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Summary
Despite advances in treatment, peritoneal infection remains one of the main 
causes of technique failure in Peritoneal Dialysis (PD) patients. Understanding 
the nature of the peritoneum’s response to inflammation is vital if we wish to 
reduce the negative impact of inflammation and infection on the peritoneal 
membrane. Given that aberrant leukocyte recruitment and activation appears to 
be a feature of these responses it is particularly important that we understand the 
contributions made by both resident and recruited peritoneal leukocytes in 
controlling this process as well as their direct contribution to membrane 
damaging events.
Data presented in this thesis has shown that the peritoneal T-cell pool is a 
heterogeneous mixture of specialized T-cell subsets. In contrast to previous 
observations, we have shown that (under appropriate conditions) these cells are 
capable of being activated, though their effector function appears to be tightly 
regulated by peritoneal dendritic cells. The phenotype and activation threshold of 
peritoneal T-cells differs markedly from that of peripheral blood T-cells in that the 
peritoneal cavity is enriched in both effector memory and regulatory T-cells. 
These cells exist in a delicate equilibrium to both maintain homeostasis and 
ensure prompt removal of invading pathogens. During episodes of acute 
inflammation (peritonitis) further specialized T-cell subsets (TH17 and Vy9S2 T- 
cells) are recruited into the peritoneal cavity. These cells form part of the early 
immune response and are a pivotal link between the innate and adaptive arms of 
the immune response.
Recurrent peritonitis has a detrimental impact on the function of peritoneal T- 
cells, impairing both the proliferation and effector function of these cells. This 
peritoneal T-cell dysfunction contributes to a state of immuno-suppression thus 
potentially rendering the patients more susceptible to further episodes of 
peritonitis. It is also likely to have a negative impact on immuno-resolution and 
contribute to neutrophil retention, chronic inflammation and membrane fibrosis.
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Chapter 1 
Introduction
1
1.1 Renal replacement therapy
1.1.1 End Stage Renal Failure
End-stage renal failure (ESRF) is a condition in which a person's kidneys 
cease to function on a permanent basis. This necessitates a form of renal 
replacement therapy (regular dialysis or a kidney transplant) to maintain life. 
At present the number of available donor kidneys falls woefully short of the 
demand, so that the majority of ESRF patients are dependant on some form 
of dialysis.
1.1.2 Haemodialysis vs. Peritoneal Dialysis
Two major forms of dialysis are currently available: Haemodialysis (HD) and 
peritoneal dialysis (PD). HD is most frequently carried out at a hospital 
dialysis unit. Blood is pumped in an extracorporeal manner through an 
artificial kidney. PD is carried out by patients at home, in this case dialysis 
fluid is instilled into the peritoneal cavity and dialysis takes place across the 
peritoneal membrane. PD has a number of advantages over HD including 
better preservation of residual renal function, maintenance of higher 
haemoglobin levels, and lower cost. PD patients also benefit from the more 
flexible nature of the treatment, which allows them to work and travel, thus 
considerably improving their quality of life [1,2].
Prevalence of patients on renal replacement therapy increases by 7-8% per 
annum in a compound manner and is therefore expected to double over the 
next ten years. In view of this, it is essential to maximise the choice available 
to patients and to provide the most cost effective type of dialysis option. It is 
established that the most benefit is obtained when patients commence 
dialysis with PD and that this delivers a better-integrated programme. 
Currently however the median time on PD is 2.5-3.5 years. Limitations 
include peritonitis, loss of residual renal function and loss of effective 
membrane function [1, 2].
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1.2 Peritoneal Dialysis
1.2.1 PD technique
The peritoneal cavity is a coelomic cavity within which the abdominal viscera 
are located. The peritoneal membrane that lines the abdominal organs is the 
visceral layer; the membrane that lines the abdominal wall is the parietal 
layer. The peritoneal cavity normally contains only a small amount of viscous 
lubricating fluid that enables unrestricted movement of the gut.
During a PD exchange, 2-3 litres of dialysis fluid is instilled into the peritoneal 
cavity via a percutaneous catheter. Uraemic toxins and solutes diffuse across 
the peritoneal membrane from blood into the dialysis fluid, which is then 
drained and discarded. The commonest PD regimen uses 3 daytime 
exchanges (each of 4h duration) and one overnight exchange (8-12h). An 
alternative PD regimen using shorter but more frequent dwells is Automated 
Peritoneal Dialysis (APD); in this case a mechanised cycler infuses and drains 
peritoneal dialysate at night allowing for more rapid fluid exchange.
1.2.2 Ultrafiltration
In addition to removing waste products, PD also removes excess body water - 
a process known as ultrafiltration (UF). In order to achieve UF, PD fluid must 
be hypertonic as compared to blood. This is achieved by the addition of an 
osmotically active agent (usually glucose) to the PD fluid. During the course 
of a dwell, this osmotic gradient dissipates as glucose is absorbed. If the 
glucose is absorbed too rapidly, the concentration gradient is lost and the UF 
achieved may be inadequate.
1.2.3 Peritoneal membrane transport kinetics
The rate at which solutes are transferred across the membrane varies, both 
from patient to patient and (in an individual patient) with time on PD. A better 
understanding of a patients membrane transport characteristics enables a 
physician to prescribe the appropriate dialysis regimen for that individual. A
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Peritoneal Equilibration Test (PET) is used to measure the rate at which 
solutes pass from the bloodstream across the membrane into the dialysis 
fluid. If solutes move quickly, the person is termed a “high transporter”; if the 
solutes move slowly, the person is termed a “low transporter”. A “high 
transporter” will have excellent solute transfer across the membrane but will 
have limited ultrafiltration capacity as the osmotic gradient dissipates too 
rapidly. These patients may benefit from more frequent exchanges with 
shorter dwell times e.g. APD. They may also benefit from the use of a 
different solution (such as one containing a glucose polymer) where the 
osmotic agent is larger and less easily absorbed [3].
1.2.4 PD adequacy
To determine whether a given PD regimen is providing “adequate dialysis” a 
clearance test is performed. This involves collecting all the PD effluent and 
urine from a 24-hour period and comparing the amount of urea and creatinine 
in the solution to the amount in the blood. From these figures a weekly urea 
clearance (termed KtA/) and creatinine clearance (CrCI) is calculated. Current 
guidelines recommend a minimum target of 1.7 for KtA/ and 60 L/wk for CrCI 
(KDOQI 2006). Clearance can be improved by increasing either the volume 
or the number of exchanges. Total clearance is significantly enhanced by the 
maintenance of residual renal function.
1.2.5 PD solution biocompatibility
Standard PD solutions have a number of characteristics that can potentially 
have an adverse effect on the homeostasis of the peritoneal cavity. These 
characteristics include low pH (necessary to prevent caramelization of 
glucose during sterilization) and a high concentration of lactate, glucose and 
glucose degradation products (GDP). These conventional PD fluids are 
referred to as being “bioincompatible”. There is abundant evidence to show 
that these fluids have detrimental effects on the cells of the peritoneal cavity. 
These findings have prompted the development of more biocompatible PD 
fluids which have a physiological pH, use bicarbonate as a buffer and have a 
low GDP content. Although laboratory studies confirm that these newer fluids 
are less cytotoxic, there remains a dearth of clinical studies showing any
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improvement in patient or treatment outcomes. Consequently many health 
care providers are (at present) reluctant to fund the prescribing of these 
newer, more expensive products [4-13].
1.2.6 PD Peritonitis
The most significant problem associated with PD therapy is peritonitis. 
Peritonitis can occur in a relatively high number of patients -  one episode per 
15 patient-months (although these figures vary considerably from unit to unit 
and from country to country) and carries both short and long-term 
consequences for the patient. (See table. 1.1)
Short-term Long-term
Hospitalisation
Transfer to haemodialysis
Mortality
Membrane failure 
Cardiovascular morbidity
Table 1.1 Complications of peritonitis [4, 5]
PD peritonitis most frequently occurs when skin commensals are introduced 
into the peritoneal cavity during the bag exchange. Patients usually present 
with abdominal pain and “cloudy” dialysis fluid. The diagnosis is supported by 
the finding of >100 white blood cells (WBC) /mm3 of dialysate (of which at 
least 50% are neutrophils). As soon as a provisional diagnosis of peritonitis is 
made, symptomatic patients are treated with empirical intra-peritoneal broad- 
spectrum antibiotic therapy. If a patient is asymptomatic (cloudy fluid, no pain 
or fever), therapy may be delayed until the Gram stain results are available 
(as long as this takes no more than 2-3hrs). Treatment is subsequently 
refined according to culture and sensitivity results.
Culture results should become available for most patients within 2-3 days, 
however in 2-20% of cases no organism is grown (culture negative 
peritonitis). Culture negative peritonitis is more likely to occur if a patient is 
already on antibiotics, if culture techniques are inadequate or if the organism
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is unusual e.g. Mycobacterium spp. The commonest organisms cultured 
during peritonitis are skin commensals such as Coagulase negative 
Staphylococcus (including Staphylococcus epidermidis or Staphylococcus 
aureus). Gram-negative infections are less common, however they are 
associated with a more severe and protracted clinical and inflammatory 
course. A mixed growth or a growth of anaerobic organisms is suggestive of 
bowel perforation [6, 7].
1.3 The Peritoneal membrane
1.3.1 Membrane structure
Critical to the success of PD is the ability of the peritoneal membrane to 
function as a selective, semi-permeable dialysis membrane. As shown in 
Figure 1.1, the peritoneal membrane has a multi-layered structure. The 
mesothelial layer is an epithelial monolayer of mesothelial cells packed 
together via tight junctions and communicating junctions. The mesothelial 
cells express microvilli, which increase the surface area of the membrane thus 
allowing greater absorption. An underlying basement membrane provides 
support for the mesothelial cell layer. The Compact Zone is a thin connective 
tissue matrix that lies beneath the mesothelial layer. The compact zone is 
made up of loosely arranged collagen fibres (Type I and III) interwoven with 
occasional elastin fibres. The compact zone provides strength and elasticity 
to the membrane. Though occasional blood vessels are seen to run through 
the compact zone, the vascular bed is maximal at the junction of the compact 
zone with the underlying adipose tissue [8].
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Figure 1.1 Structure of the normal peritoneal membrane [19].
B
2500
2000
£ c. 1500n ©
2ts 1000
( 0  CO
500
13 29 55 63 26 17 21 30
^  f t  f t  f t  of
\  r ’
, s " - \ ‘ - 4  ■' - iS * .
Time on PD 
(months)
4<- V <
'% 'IV ^ V >  * 4 - •,,• iA .
:• . • ■ t  ■■■•
 i   ■■■».,, : ;.,-
Figure 1.2 Changes in the peritoneal membrane with time on PD. (A) Long term PD 
is associated with an increased compact zone thickness. (B) A parietal peritoneal biopsy 
showing characteristic mesothelial loss and collagen deposition in the sub-mesothelial 
compact zone [18,19].
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1.3.2 Changes in the peritoneal membrane with time on PD
Long term PD is associated with characteristic membrane changes (Figure 
1.2). Loss of mesothelial cells is a well-described, almost universal feature. 
The remaining mesothelium is often abnormal, displaying degenerative 
changes with loss of cytoplasmic organisation [9]. An increase in thickness of 
the compact zone occurs, broadly related to time on dialysis. This is 
characterised by changes in extracellular matrix turnover and deposition that 
leads to irreparable deposition of a dense collagenous matrix [8-10]. PD 
associated vascular changes include sub-endothelial hyalinization, intimal 
distortion and eventual venule obliteration. These have been described as 
being associated with advanced glycation end products (AGE) accumulation 
[8-11]. These alterations in membrane structure are collectively termed 
membrane fibrosis. They are associated with detrimental functional changes 
including an increase in solute transport and the loss of ultrafiltration capacity. 
Ultimately this can lead to technique failure and transfer to HD [8, 10, 12].
1.3.3 The aetiology of membrane fibrosis
Though the aetiology of membrane fibrosis is multi-factorial, the two most 
important factors have been identified as exposure of the membrane to the 
bioincompatbile components of PD solutions and episodes of peritonitis.
1.3.3.1 Exposure to bioincompatible PD fluids
Studies have suggested that cumulative exposure to the bioincompatible 
components of PD fluid is associated with membrane fibrosis [13-15]. 
Glucose itself is a potent activator of human peritoneal mesothelial cells 
(HPMC), inducing production of fibronectin and transforming growth factor 
beta (TGFp). PD fluid may also contribute to membrane damage via the 
presence of GDP and the formation of advanced glycation end products 
(AGE). In vitro studies have shown that certain GDP inhibit mesothelial 
wound healing while in vivo murine studies suggest that they contribute to 
angiogenesis and fibrosis. AGE are thought to disrupt numerous processes 
including chemotaxis, matrix cross-linking and inflammation. Increased AGE 
deposition has been correlated with increased membrane fibrosis suggesting 
a causal relationship. Additionally, both glucose and lactate together drive
8
production of intracellular sorbitol via the polyol pathway. Blocking the polyol 
pathway in the rat model has been shown to reduce membrane fibrosis and 
angiogenesis suggesting that intracellular sorbitol is detrimental to membrane 
survival [9, 13, 19-21,25-31].
1.3.3.2 Recurrent peritonitis
There is a strong association between peritonitis (frequency and severity) and 
the loss of membrane function. Peritoneal biopsy data shows that progressive 
fibrosis, vasculopathy and UF failure are far more likely to occur in patients 
who suffer from peritonitis (see Figure 1.3). These biopsy findings are 
mirrored by observations in the murine model which have shown that 
repeated episodes of peritoneal inflammation result in membrane fibrosis [8- 
10, 12, 16].
1.4 Immunobiology of the peritoneal Cavity
1.4.1 Peritoneal macrophages (PM0)
The peritoneal cavity contains a specialised population of resident leukocytes 
(macrophages, lymphocytes and dendritic cells), which together with the 
mesothelial cells constitute the cellular arm of the peritoneal immune system 
(see Figure 1.4). The PM0 are the most abundant (70-80%) and the most 
widely studied of the peritoneal resident leukocyte population. During 
episodes of peritonitis, their two primary functions are phagocytosis of 
invading bacteria and the production of inflammatory mediators such as IL-1 p 
and TNFa. With time on PD, PM0 display a progressively more immature 
phenotype, increasing the expression of CD15 and CD71 (both markers of 
immaturity) and down regulating expression of CD11c (a marker of maturity). 
These phenotypic changes are associated with functional deficiencies 
including decreased bactericidal activity, decreased phagocytic activity and 
impaired cytokine production. Recurrent episodes of peritonitis appear to 
accelerate the progression of these detrimental functional changes [17-22].
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Figure 1.3 Effect of recurrent peritonitis on membrane thickness. Previous peritonitis 
is associated with increased sub-mesothelial compact zone thickness [18],
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Figure 1.4 Immunobiology of the peritoneal cavity. Circulating leukocytes are 
selectively recruited from the systemic circulation into the peritoneal cavity.
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1.4.2 Human peritoneal mesothelial cells (HPMC)
Mesothelial cells were once regarded as a passive lining to the peritoneal 
cavity, however we now realise that this is not the case. These cells are an 
integral part of the peritoneal immune response; indeed during peritonitis the 
HPMC are the main source of many pivotal chemokines (chemotactic 
cytokines) such as interleukin 8 (IL-8) and monocyte chemoattractant protein- 
1 (MCP-1). In addition to their secretory function, in vitro evidence suggests 
that mesothelial cells can also become potent antigen presenting cells (APC). 
Once activated they express MHC class 2 molecules on their surface, thus 
allowing them to present processed antigen to T-cells. This function is aided 
by constitutive expression of intercellular adhesion molecule-1 (ICAM-1, the 
major accessory molecule expressed by non-professional APC) on their 
surface [22-25].
Long term PD therapy is associated with a reduction in total number of 
mesothelial cells; additionally the remaining cells adopt an abnormal 
morphological appearance suggesting that PD therapy may be detrimental to 
their function and survival [8,10].
1.4.3 Peritoneal dendritic cells (DC)
Immature DC are found in peripheral tissues where they constantly sample 
the external environment via receptor-mediated endocytosis. They possess 
specialised pattern recognition receptors (PRR), which recognise highly 
conserved microbial antigens known as pathogen associated molecular 
patterns (PAMP). One group of PRR are the Toll like receptors (TLR), which 
can activate cell signalling and DC activation. Once activated, DC upregulate 
expression of antigen loaded MHC molecules and express lymph node 
homing signals such as the chemokine receptor CCR7. DC maturation is 
accompanied by up-regulation of T-cell co-stimulatory molecules such as 
CD80 and CD86 [26, 27].
Very little was known about the precise phenotype and function of peritoneal 
DC until recently when investigators characterised a small subset (5-6%) of
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CD14+CD4+ cells, which fulfil the definition of DC pre-cursors. As compared 
to PM0, these pre-DC1 cells express higher levels of co-stimulatory 
molecules, and are potent stimulators of allogenic T cells. Under appropriate 
conditions the pre-DC1 cells have the capacity to differentiate further, 
acquiring the morphological characteristics of mature DC [26, 27]. The 
number of pre-DC1 cells increases during the course of peritonitis suggesting 
that these cells are specifically recruited into the inflamed peritoneal cavity. 
Given that they express both PRR and MHC class II molecules, it is likely that 
they form a pivotal link between the innate and adaptive arms of the 
peritoneal immune response (see later). The impact that PD therapy has on 
the function of these cells is, at present unknown [17, 27, 28].
1.4.4 Peritoneal lymphocytes
There is relatively little data available regarding the phenotype and function of 
human peripheral tissue lymphocytes. This is due in part to the logistical 
difficulties involved with sample collection and the (usually) low yield of cells 
obtained from peripheral sites. The natural corollary of this is that most of our 
knowledge regarding human lymphocyte biology has been gained from 
animal models, cell lines and studies of peripheral blood lymphocytes.
A few studies have attempted to characterise the resident peritoneal 
lymphocytes. Most have focused on the surface phenotype of these cells with 
very little functional analysis. From these studies we can conclude that 
peritoneal lymphocytes represent between 10-30% of the resident peritoneal 
cell population. The majority of these are peritoneal T-cells with a smaller 
population of peritoneal B-cells (3-5%) and Natural killer (NK) cells ( 1-2%). 
When compared to peripheral blood lymphocytes, a large proportion of 
resident peritoneal T-cells express surface markers of activation such as 
CD69 and HLA-DR. They also display increased expression of CD45R0, 
which has been associated with memory cells [29-33]. The phenotype and 
function of peritoneal NK and B-cells remain poorly defined in the PD 
population. NK cell numbers appear to increase with time on PD, however 
their recruitment profile and effector function during peritonitis is not well 
documented [34, 35]. Given that NK cells are a pivotal part of the innate
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immune response, it is likely that they are recruited early in the course of 
peritonitis along with neutrophils and inflammatory monocytes [36].
1.4.5 Peritoneal Mast Cells
Despite representing only a small proportion of the total PD effluent 
leukocytes (<1%), mast cells are frequently observed in peritoneal membrane 
biopsy specimens. In addition to their well documented role in allergic 
responses and immune response to parasites, more recent evidence 
suggests that these tissue resident mast cells play an important role in the 
early phase of the immune response. Mast cell depletion attenuated both KC 
production and neutrophil accumulation in the murine model of peritonitis. 
The number of resident peritoneal mast cells decreases with time on PD, 
which may in turn compromise the host “innate” immune response. [37, 38]
1.4.6 Peritoneal milky spots
Peritoneal milky spots were first described by Recklinghausen in 1863 and 
have since been identified as a pivotal component of the peritoneal immune 
defence. Milky spots are found within the omentum and appear as dense 
corpuscles to the naked eye. They are devoid of a capsule and contain 
aggregates of macrophages, B-cells, T-cells and mast cells. During bacterial 
peritonitis, milky spots increase dramatically in both size and number 
becoming easily visible to the naked eye as “cotton wool-like” masses [39, 
40].
Numerous studies have highlighted the importance of peritoneal milky spots in 
orchestrating the host defence against invading pathogens. Peritoneal 
macrophages have been shown to undergo proliferation, differentiation and 
maturation locally within the milky spots. In addition they serve as a “relay 
station”, regulating transit of B-cells from the circulation into the peritoneal 
cavity. Peritoneal milky spots are clearly an active site of leukocyte migration 
and are thus an important source of “primed” effector cells during bacterial 
peritonitis [41, 42].
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The impact of PD therapy on peritoneal milky spots has been studied in both 
animals and humans. In a rat model of PD, exposure of the peritoneum to 
some of the more bio-incompatible components of PD solution (low pH, 
lactate and GDPs) resulted in a significant increase in both the number and 
diameter of milky spots [42, 43]. Analysis of human peritoneal biopsies 
suggests that with time on PD, milky spots appear to increase significantly in 
size. Collectively these studies suggest that PD therapy in itself may trigger a 
localized inflammatory response within the peritoneal cavity [40, 44].
1.5 The peritoneal immune response
1.5.1 Early vs. late phase
During an episode of peritonitis the various cellular components of the 
peritoneal immune system must work in conjunction to mount an effective 
peritoneal defence. The readily accessible nature of PD has allowed detailed 
analysis of the temporal changes in leukocyte phenotype that occur during an 
episode of peritonitis. The immune response is broadly divided into early and 
late phases. The early phase is characterised by a rapid influx of neutrophills, 
which are rapidly cleared and replaced by a slower, more sustained influx of 
mononuclear cells (Figure 1.5) [45-47].
The terms “innate” and “adaptive” are often used when referring to the early 
and late phases of the immune response. This is not strictly correct and may 
lead to confusion since the terms innate and adaptive refer to the specific 
nature of the response rather than to its temporal profile. The innate 
response describes a non-specific, highly stereotypical response to pathogen 
invasion, which is devoid of a memory component. In contrast to this, the 
adaptive immune response is a highly antigen-specific response 
characterised by long-term immunological memory. It is clear that some cells 
participating in the later phase of the immune response are in fact part of the 
innate immune system whereas some T-cells (the hallmark “adaptive” cells)
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Figure 1.5 The peritoneal immune response; early vs. late. Recruited neutrophils 
are rapidly cleared and replaced by a slower, more sustained influx of mononuclear 
cells [50-52],
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may play an important role in the very early phase of the immune response 
[45-47].
1.5.2 Peritoneal leukocyte recruitment
Peritonitis triggers a multifaceted, co-ordinated series of events, involving both 
innate and adaptive arms of the immune response. This tightly controlled 
response to infection serves to eradicate the invading organism whilst 
minimising host damage. Critical to the success of this process is the 
controlled migration of leukocytes from the peripheral blood into the peritoneal 
cavity [46, 47].
Leukocyte recruitment is a multi-step process mediated by chemokines, 
selectins and integrins. PM0 derived inflammatory signals induce up- 
regulation of vascular endothelial adhesion molecules such as selectins and 
ICAM-1. Concurrently mesothelial derived chemokines are transduced across 
the vascular endothelium and are displayed to circulating leukocytes. 
Peripheral blood leukocytes that express the appropriate chemokine receptor 
repertoire undergo a series of adhesion steps (tethering, rolling and arrest), 
which are mediated via selectins, integrins and GPCR (G-protein coupled 
receptors). Once a leukocyte is bound tightly to the endothelial surface, 
transmigration (diapedesis) is initiated [48].
The peritoneal chemokines are subdivided into 2 main groups. CC- 
Chemokines attract mononuclear cells to sites of inflammation. The best- 
characterised CC Chemokine is Monocyte Chemoattactant Molecule 1 (MCP- 
1). The second group are termed CXC chemokines (since they have a single 
amino acid between the first two cysteines). A sub-family of CXC chemokines 
carry a characteristic glutamate-leucine-Arginine (ELR) motif. A key function 
of the ELR+ CXC chemokines is to attract neutrophills to sites of 
inflammation. IL8 (CXCL8) is the prototype CXC chemokine [49].
Chemokine production and the associated leukocyte migration follows a 
tightly regulated temporal pattern. ELR+ chemokines are produced on day 1, 
leading to recruitment and intra-peritoneal accumulation of neutrophils.
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Mesothelial cells then switch production from CXC-chemokines to CC- 
chemokines, resulting in the recruitment of mononuclear cells 
(lymphocytes/monocytes/DC) from the blood [50]. Recently it has become 
evident that IL-6 signalling is pivotal in regulating this recruitment process. 
Two pathways of IL-6 signalling have been described (Figure1.6).
IL-6 trans-signalling confers IL-6 responsiveness in cell types lacking 
expression of the cognate IL-6 receptor e.g. HPMC. During peritonitis, slL-6R 
levels rise dramatically (due in part to the shedding of membrane bound 
cognate IL-6R from the recruited neutrophils) thus conferring IL-6 
responsiveness to HPMC. Both in vivo and in vitro studies have shown that 
IL-6 trans-signalling down regulates HPMC IL-8 production and increases 
MCP-1 expression, hence attenuating neutrophil recruitment and promoting 
MNC recruitment. IFN-y has also been shown to regulate neutrophil 
recruitment, due in part to its ability to act in synergy with IL-1 p and TNFa to 
promote IL-6 production [46, 47, 50-53].
1.5.3 Immuno-resolution
In addition to appropriate recruitment, a successful immune response also 
requires prompt removal of inflammatory leukocytes. This ensures minimal 
host damage and prevents the development of chronic inflammation. Within 
the peritoneal cavity an elegant IL-6-dependant control mechanism exists to 
ensure that activated neutrophils are efficiently cleared. Firstly, IL-6 trans­
signalling leads to decreased recruitment (as mesothelial cell ELR+ CXC 
chemokine production is down-regulated). Secondly, IL-6 trans-signalling 
(driven by IFN-y induced IL-6 production) have been shown to promote 
neutrophil apoptosis. This ensures prompt resolution of the early 
inflammatory response [46, 47, 50-52]. A schematic representation of the 
peritoneal response to infection is shown in Figure 1.7.
1.5.4 Chronic inflammation and membrane fibrosis
There is growing evidence from both human studies and the murine model of 
peritoneal inflammation that repeated or severe episodes of peritonitis disrupt
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Figure 1.6 IL-6 signalling pathways. (A) classic pathway: IL-6 signalling binds its 
cognate receptor on the cell surface. (B) IL-6 trans-signalling: IL-6 binds a soluble 
receptor (slL-6R) to form a ligand-receptor complex, which can activate cells by binding, 
to the ubiquitously expressed signal transducing element gp130 [51,52,57].
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Figure 1.7 The peritoneal immune response. (A) Peritoneal inflammation is initiated 
at the HPMC/pathogen interface. Activated neutrophils exit the circulation and follow a 
gradient of HPMC derived IL-8 to enter the peritoneal cavity.(B) Apoptotic neutrophils 
shed their IL-6R which in turn binds intraperitoneal IL-6. This allows HPMC to respond 
to IL-6 via trans-signalling. HPMC chemokine production switches from IL-8 to MCP-1, 
which abrogates neutrophil recruitment and attracts mononuclear cells from the 
circulation (adapted from McLoughlin et al [50]).
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the intricate control mechanisms that regulate the peritoneal immune response. 
This leads to dysregulated inflammation characterised by neutrophil retention 
and on-going production of pro-inflammatory chemokines (even in the absence 
of on-going infection). These detrimental changes herald the onset of chronic 
peritoneal inflammation, a process that is likely to initiate or perpetuate the 
development of peritoneal membrane fibrosis (Figure 1.8).
1.6 An emerging role for peritoneal T-cells
Most of our understanding of the human peritoneal immune response is 
based on in-vitro analysis of PM0 and HPMC. The role of the peritoneal T- 
cell in this process has been largely ignored. There is however evidence to 
suggest that peritoneal T-cells play a key role in orchestrating the peritoneal 
immune response. Firstly, elevated levels of T-cell derived cytokines such as 
IFN-y have been detected during episodes of peritonitis suggesting that 
significant effector T-cell activation is occurring [23, 54, 55]. Secondly, data 
derived from knockout mice studies have shown that T-cell derived cytokines 
(in particular IFN-y) are critical in regulating leukocyte recruitment during 
peritonitis. Finally, more recent data emerging from the mouse “repeat hit 
model” model of peritonitis suggests that repeated episodes of peritonitis alter 
resident peritoneal T-cell phenotype and function, and that this may contribute 
to chronic inflammation [Topley, Jones, unpublished data]. In spite of this, 
many questions remain regarding both the nature and activation status of 
human peritoneal T-cells and their precise contribution to the regulation of the 
immune responses in PD patients.
In trying to define their role in peritoneal inflammation, we have to take into 
account that the field of T-cell biology has moved on significantly over the last 
5 years, giving us fresh insight into the dynamics of T-cell development, 
activation and differentiation. The most relevant discoveries made will now be 
summarised.
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Figure 1.8 Dysregulated leukocyte trafficking. Chronic inflammation is characterised 
by aberrant recruitment and retention of activated leukocytes.
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1.6.1 T-cell development and activation
Immature T-cells generated in the bone marrow migrate to the thymus where 
they undergo a series of maturation steps including positive (for cells that 
recognise self-MHC molecules) and negative (against self-reactive T-cells) 
selection. The minority of cells that survive this maturation process (less than 
2%) exit the thymus to join the peripheral T-cell pool. These cells are known 
as naive T-cells; they are yet to encounter antigenic stimulation and display 
minimal effector function [56]. Each naive T-cell expresses a clonal, antigen- 
specific T-cell receptor (TCR). The TCR gene locus contains constant (C), 
variable (V), diversity (D) and joining (J) segments each of which exist in 
multiple copies. The vast TCR structural diversity (necessary to deal with 
millions of potential antigens) is generated by the combinatorial joining of 
these gene segments [56].
T-cell activation and differentiation is initiated when the T-cell receptor (TCR) 
of a naive T-cell interacts with the peptide-MHC (major histocompatibility 
complex) displayed on the surface of antigen-presenting cells (APC). A three- 
signal model has now emerged for T-cell activation. The first signal is 
provided by the recognition of peptide:MHC complex by the TCR, the second 
signal is provided by co-stimulatory molecules present on the surface of APC 
(e.g. CD80, CD86 and CD40) and signal three refers to the cytokines (e.g. IL- 
12) that modulate T-cell differentiation [27].
1.6.2 TH1 vs. TH2 differentiation
Following activation, naive T-cells proliferate and differentiate into a variety of 
effector cell fates that help determine the shape and effector capacity of the 
immune response. The TH1 vs. TH2 theory describes two separate T-cell 
effector subsets. TH1 cells drive cell mediated immune responses and are 
essential for the eradication of intracellular pathogens such as bacteria and 
viruses. Cytokines produced by TH1 cells stimulate macrophages to produce 
reactive oxygen species and nitric oxide. In addition, they increase 
macrophage phagocytic function and enhance MHC class II presentation.
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The hallmark TH1 cytokine is IFN-y [56, 57]. TH2 cells produce IL-4, IL-5
and IL-13 all of which can activate mast cells and eosinophills. TH2 cells also 
provide B-cell help and aid immunoglobulin class switching to the IgE 
subtype. TH2 cells predominate during nematode and helminth infection and 
have also been implicated in the pathogenesis of allergy and atopic reactions 
[56, 58, 59].
The major inducers of TH1 and TH2 subset development are DC derived 
cytokines. IL-12 is a strong driving force for a TH1 type response while 
production of IL-4 early in an immune response directs the development of 
TH2 type cells. A reciprocal control mechanism exits whereby development 
of one subset is promoted at the expense of another e.g. IFN-y up-regulates 
the expression of the IL-12 receptor but inhibits the growth of TH2 cells, 
conversely IL-4 antagonizes TH1 development (Figure 1.9). This regulatory 
mechanism streamlines the immune response by promoting the development 
of one TH subset at the expense of the other. The main transcription factors 
involved in TH1 vs. TH2 responses have been identified as T-bet and GATA- 
3 respectively [55, 60, 61].
1.6.3 IL-17 producing T helper cells (TH17)
One of the most significant challenges to the TH1/TH2 model came with the 
observation that cell-mediated tissue damage in experimental allergic 
encephalomyelitis (EAE) was not mediated by IFN-y, in fact IFN-y appeared 
to be protective against disease. This observation was surprising at the time 
since EAE (an animal model of multiple sclerosis) was thought to be the 
archetypal TH1-mediated disease [61, 62].
Their discovery stemmed from work done on IL12/IL-23 double-deficient mice. 
Both IL-12 and IL-23 are heterodimers containing a p40 sub-unit in 
combination with a second sub-unit. In the case of IL-12 this is p35 whereas 
for IL-23 the second sub unit is p19. This subtle difference allowed 
investigators to manipulate IL-12/IL-23 signalling pathways by creating mice 
deficient in either the p40, p35 or p19 sub units. Experiments with these mice
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Figure 1.9 TH1 vs. TH2 effector T-cell development [60-65].
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revealed that both p19'/_ mice (deficient in IL-23 signalling) and p40'/_ mice 
(deficient in both IL-23 and IL-12 signalling) are protected against EAE 
whereas p35_/' mice (deficient in IL-12 signalling) still develop the disease. 
These findings were the exact opposite of what would have been predicted 
from the TH1 model of EAE pathogenesis and suggested that the disease 
was not in fact driven by the IL-12/IFN-y axis. Further experiments delineating 
the role of IL-23 in this process led to the discovery of a unique, highly pro- 
inflammatory IL-17 producing T-cell subset (TH17) [61, 62].
Since their discovery, TH17 cells have been implicated in the pathogenesis of 
numerous murine models of disease such as EAE, myocarditis, inflammatory 
colitis, collagen induced arthritis and airway hypersensitivity. There is also a 
growing body of evidence suggesting that IL-17 plays a role in human disease 
such as multiple sclerosis, rheumatoid arthritis, graft rejection and psoriasis 
(indeed anti-p40 treatment is currently being investigated as a potential 
therapy for psoriasis) [61].
The precise cytokine milieu necessary to drive TH17 development remains an 
area of controversy. Initial observations in the EAE model suggested that IL- 
23 signalling was essential, however this was challenged by series of 
experiments revealing that transforming growth factor beta (TGFp) in the 
presence of IL-6 is sufficient. It appears that both findings are correct, since 
although IL-23 is not necessary for TH17 development, it is essential for their 
survival and effector function. In addition to IL-17, TGFp driven TH17 cells 
also produce IL-10, so that IL-23 is required to overcome the anti­
inflammatory effects of IL-10 [62-65].
Similar to TH1/TH2 regulation, a reciprocal control mechanism exists between 
TH1 and TH17 subsets with one subset preventing development of the other. 
The key transcription factor necessary for TH17 development has now been 
recognised as the orphan nuclear receptor RORyt [62-65].
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1.6.4 Regulatory T cells (T-regs)
A key feature of the immune system is the ability to discriminate between self 
and non-self. This ensures effective clearance of microbial pathogens but 
prevents the development of autoimmune disease. Thymic deletion or 
inactivation of self-reactive T-cells (clonal deletion/anergy) helps to maintain 
self-antigen tolerance. This mechanism is not fail-safe and significant 
numbers of self-reactive T-cells avoid deletion and enter the peripheral 
circulation. Additional protection against autoimmunity is provided by the 
presence of a population of circulating (and local) regulatory T-cells (T-regs).
T-regs are able to prevent autoimmune disease by suppressing the effector 
function of potentially self reactive T-cells. In addition to their well 
documented role in preventing autoimmunity more recent evidence suggest 
that these cells play a role in regulating the host response to malignancy, 
infection and allogenic organ transplants [66, 67].
Although initially described in the 1970’s, a phenotypic description of T-regs 
did not become available until the mid 1990’s. Murine experiments performed 
at that time showed that CD4+ T-cells expressing the IL-2 receptor 
(CD4+/CD25+ T-cells) were able to suppress the development of 
experimentally induced autoimmune disease. Unfortunately, this early 
phenotypic definition fails to distinguish T-regs from recently activated effector 
CD4 cells (as both express CD25). Similarly, the specificity of other T-reg 
surface markers such as LAG-3, CTL-4 and GITR (Glucocorticoid-induced 
Tumour necrosis factor receptor family related protein) are limited by the fact 
that recently activated effector and memory T cells also express these 
markers. The more recent discovery of Foxp3 (a member of the forkhead 
family of transcription factors) has allowed a more refined phenotypic 
description of T-regs [68-71].
Foxp3 is thought to be the first specific marker of T-reg cells, discriminating 
between T-regs (CD4+/CD25+/Foxp3+) and activated effector T-cells 
(CD4+/CD25+ /Foxp3 ). The importance of Foxp3 in T-reg development and 
function is highlighted by observations in both the murine and human system. 
Mice deficient in Foxp3 lack T-reg cells and develop multi-organ autoimmune
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pathology, whereas in humans Foxp3 mutations cause the autoimmune 
phenomenon known as IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X linked syndrome) [68-71].
A recent sub-classification divides T-regs into natural T-regs (generated within 
the thymus during the process of T-cell maturation) and inducer T-regs (which 
develop from CD4+CD25‘ naive T-cells in the periphery). As compared to 
natural T-regs, inducer T-regs express lower levels of CD25 and are more 
dependant on TGFp for their development and effector function [72-74]. 
Inducer T-regs appear to have close ties with the TH17 subset since both are 
believed to differentiate from the same precursor cell and a model has been 
proposed whereby they work in conjunction to restrict or elicit tissue 
inflammation (Figure 1.10).
The T-reg/TH17 development hypothesis has challenged many theories 
regarding pro- and anti-inflammatory response by showing that a TH1 
response (by preventing TH17) can in fact be anti-inflammatory while T-regs 
(via production of TGFp) may sometimes have a pro-inflammatory effect [61].
1.6.5 Gamma delta T-cells (y6 T-cells)
Whilst the majority of circulating T-cells express the TCRap (apT-cells) on 
their surface, a minority (2-20%) express the TCRyS. In humans the most 
abundant y8 T-cells is the subset expressing the Vy982 TCR. There is 
emerging evidence that these cells orchestrate the early phase of the immune 
response [75]. Vy982 T-cells differ fundamentally from ap T-cells with respect 
to the type of antigen recognised, mode of antigen recognition and chemokine 
receptor profile. With regards to antigenic stimulation, Vy982 T-cells 
recognise low molecular weight non-peptide compounds in an MHC 
independent manner. This is in stark contrast to ap T-cells that recognise 
peptides presented on MHC molecules by APC [75-78].
The most potent stimulant of Vy982 T-cells is E-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMB-PP), an intermediate of the microbial non-mevalonate
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Figure 1.10 The balance between T-regs and TH17 cell development (A) During the 
steady (non-infected) state T-regs dominate and suppress TH1 and TH2 cell effector function. 
(B) During infection, microbial products trigger DC (via Toll-like receptors) to produce large 
amounts of IL-6 and IL-23, which together with TGFp increase the rate of TH17 cell 
differentiation. IL-23 promotes the proliferation and inflammatory function of these cells. (C) 
Later in the course of infection, TH1 and TH2 cells pre-dominate and (via IFN-y and IL-4), 
inhibit TH17 cell differentiation and function. Finally, as infection subsides inflammatory T-cells 
are cleared, T-regs pre-dominate and homeostasis is restored (reproduced from Cua et al 
[70]).
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pathway of isopentenyl pyrophosphate (IPP) biosynthesis. The ability to 
recognise a by-product of a key metabolic pathway shared by numerous 
organisms (but absent in all higher eukaryotes) offers a simple means for 
Vy9S2 T-cells to respond to a host of different pathogens. Common infective 
agents that utilise the non-mevalonate pathway include, Mycobacterium 
tuberculosis, Plasmodium falciporum and most Gram-negative organism 
species including Pseudomonas spp. and Escherichia coli. Interestingly, 
Streptococci and staphylococcal species (like eukaryotes) utilise the classical 
pathway of IPP biosynthesis, hence do not produce HMB-PP and do not 
stimulate Vy9S2 T-cells in vitro [75].
In contrast to peripheral blood ap T-cells most Vy952 T-cells express an 
inflammatory chemokine receptor profile characterised by increased 
expression of CCR5 (and decreased expression of CCR7). This “inflammatory 
phenotype” is shared by neutrophils, monocytes and immature DC and 
suggests that Vy9S2 T-cells respond early during the course of an 
inflammatory episode. Once at the site of infection, Vy952 T-cells up-regulate 
lymph node homing receptors and develop potent antigen processing 
capabilities (similar to mature DC). This suggests that they have the potential 
to activate ap T-cells, thus triggering the adaptive immune response (see 
later) [75-78].
1.6.6 T cell memory
Following prolonged stimulation of the TCR, most effector T-cells undergo 
activation-induced cell death (AICD). A small percentage of those that survive 
persist as long-lived memory T-cells, providing recall responses to the primary 
antigenic stimulus. A classification of T-cell memory subsets has been 
proposed based on the expression of the lymph node homing signals CCR7, 
CD62L and the memory cell marker CD45R0 (Figure 1.11)[59, 79].
Effector memory (Tem ) cells (CD45R0/CD62LLo /CCR7 ) express receptors 
that allow them to migrate to inflamed areas. Upon stimulation, Tem display 
immediate effector function [59,80]. Central memory (T cm ) cells
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Figure 1.11 T-cell memory subsets. Memory subsets are defined by their expression 
of CCR7, CD62L and CD45R0 (64,83).
30
(CD45R0/CD62LHi /CCR7+) express receptors for lymph node migration and 
lack immediate effector function. They retain their proliferative capacity and 
efficiently differentiate into effector cells [59, 80]. Terminally Differentiated 
Effector memory cells (TEMRA) (CD45RA/CD62Lo/CCR7 ) are found in the 
CD8 population. These are thought to be Tem cells which express CD45 RA 
rather than CD45R0 [59, 80].
The existence of such functionally distinct memory subsets provide an 
effective defence mechanism against infection as Tem provide immediate 
protection while Tcm provide a secondary response and long term protection. 
Two different pathways of T-cell memory differentiation have been postulated, 
these are outlined in Figure 1.12 [59, 79, 80].
Unlike short lived effector T-cells, memory cells can persist for a lifetime even 
in the absence of antigen. This longevity is dependant on the presence of 
cytokines such as IL-7 and IL-15, which maintains homeostatic proliferation, 
and prevents cell removal by apoptotic mechanisms. IL-7R expression has 
recently been identified as a useful phenotypic memory cell marker, which 
may distinguish between memory cells and short-lived effector cells [80].
1.6.7 A current paradigm of apT-cell diversity
The advances in the field of T-cell biology (summarised in Figure 1.13) serve 
to highlight how little we know regarding the phenotype and function of the 
peritoneal T-cell population. Since most peritoneal T-cell studies are over 10 
years old, they pre-date the recognition of most of the subsets described 
above. Consequently it is hardly surprising that none of these cells have been 
identified in the peritoneal cavity of PD patients. Moreover since most human 
studies have focussed on peripheral blood, there is a general paucity of data 
describing these cells in any peripheral tissue.
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Figure 1.12 Memory T-cell differentiation. (A) According to the linear model, memory 
cells arise directly from effector cells which have reverted to a quiescent state. The TCM 
serve as a pool of memory cells capable of replenishing the TEM pool. (B) According to 
the progressive model, the fate of the naive cells depends on the duration and strength of 
the antigenic stimulus. A strong, prolonged stimulus leads to the generation of effector 
cells. A weaker stimulus leads to the production of non-effector intermediates which serve 
as a pool of highly sensitive cells that can be recruited in the secondary immune response. 
One type of cell migrates to peripheral tissue and displays immediate effector function, the 
other type migrates to lymph nodes and lacks immediate effector function [83]
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Figure 1.13 A current paradigm of afTT-cell differentiation encompassing some of 
the more recent developments
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1.7 Scope of this thesis
Appropriate regulation of leukocytes and the mediators responsible for their 
recruitment and clearance is a hallmark of competent host defence and the 
resolution of inflammation. Understanding and modifying the potentially 
detrimental pathways of the immune response is vital if we wish to limit the 
exposure of the peritoneal membrane to prolonged inflammation. To this 
extent, information about resident peritoneal T-cells during prolonged periods 
of PD is sparse, and their impact on the development of membrane fibrosis 
may have been severely underestimated. Observations from the mouse 
“repeat hit model” suggest that dysregulation of the resident T-cell population 
may initiate chronic inflammation and membrane fibrosis. We feel that a 
contemporary phenotypic and functional analysis of the peritoneal T-cell 
population is essential if we are to understand the basic disease mechanisms 
that trigger immune dysregulation, chronic inflammation and membrane 
fibrosis.
The specific aims of each investigative chapter are as follows:
Chapter 3 has characterised the basic phenotype, activation status and 
function TH1/TH2-polarisation, proliferation of resident peritoneal T-cells.
Chapter 4 identifies specialised T-cell subsets (including memory, T-regs, 
TH17 and Vy962 subsets) within the resident peritoneal T-cell population.
Chapter 5 identifies the impact of recurrent infection on resident peritoneal 
T-cell phenotype and function.
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Chapter 2 
Materials and Methods
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2.1 Patient selection
Ethical approval was obtained from the South East Wales Ethics Committee 
(04WSE04/27). Consenting patients were recruited from the University 
Hospital of Wales PD Unit. Unless specifically stated, all patients were 
receiving a standard peritoneal dialysis therapy of four exchanges per day 
with 2 litres of dialysis fluid (Dianeal ± Extraneal; see appendix section for 
further details on PD prescriptions).
2.2 Leukocyte isolation from PD fluid
PD effluent (mean drained volume 2187ml, range 1585-3120ml) was collected 
from patients after an overnight 8-1 Oh dwell. Samples were collected on ice 
to reduce adhesion of cells to the PD bag [81]. Following collection the PD 
effluent was aliquoted into 50ml tubes (Sarstedt AG & Co, Numbrecht, 
Germany) and centrifuged at 3000 rpm (2133xg), at 4°C for 35mins (Minifuge 
T, Heraeus/Kendro Laboratory products, Stevenage UK). The cell pellets 
were re-suspended in 50ml phosphate buffered saline (PBS, Sigma-Aldrich, 
Kent, UK). The cell suspension was centrifuged at 4°C for 20 mins at 3000 
rpm (2133xg). The supernatant was discarded and the cell pellet was re­
suspended in lysis buffer (see section 2.15) and allowed to stand for 5 mins at 
room temperature. The suspension was re-centrifuged at 3000 rpm (2133xg) 
at 4°C for 20mins and the pellet re-suspended in PBS at 1x106 cells/ml (mean 
number of leukocytes/bag was 6.4x106, range 1.0-25x106). Leukocyte 
numbers obtained from the overnight pd effluent of an individual (stable) 
patient remained constant over a 3/4 month collection period.
2.3 Leukocyte isolation from peripheral blood
Venous blood was collected from consenting healthy laboratory volunteers/ 
patients in an ethylene-diamine-tetra-acetic (EDTA) vacutainer tube (Becton
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Dickinson Ltd., Oxfordshire, UK) and centrifuged at 1299 rpm (400xg) for 
12mins. (Minifuge T, Heraeus/Kendro Laboratory products, Stevenage UK). 
After discarding the plasma, the remaining blood cells were re-suspended in 
an equal volume of PBS. The cell suspension was layered onto Ficoll-paque 
(Amersham Biosciences Ltd, Bucks, UK) and centrifuged at 1299 rpm 
(400xg), at 10 C for 35 mins. The mononuclear cell layer (formed at the 
interface) was aspirated into a 50ml tube and suspended in 10ml of PBS at 
10 C. The cell suspension was centrifuged at 10 C for 10mins at 1299 rpm 
(400xg). The supernatant was discarded and the cell pellet re-suspended in 
lysis buffer (see section 2.15) and allowed to stand for 5mins at room 
temperature. The suspension was re-centrifuged at 1299 rpm (400xg) at 10 C 
for 10mins and the pellet was washed (x3) prior to suspension in PBS at 
1x106cells/ml.
2.4 Total cell count
Total cell count was determined using a Coulter Counter (Z2, Beckman 
Coulter, Buckinghamshire, UK). One hundred pi of the cell suspension was 
diluted in 20ml of Isoton II solution (Beckman Coulter, Buckinghamshire, UK) 
in a counting vial and placed in the machine. The coulter Counter analyzed 
0.5ml of sample.
The number of cells per ml was calculated
(A1 - B1) + ( A2 - B2) x 2 x 2000 = Total cell number 
2
A = Total cell count of the sample
B = Total background count of clean Isoton II in a counting vial
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2.5 Differential cell count
Cytospin preparations were prepared to assess the differential cell counts. 
Samples of cell suspension were added to the cytocentrifuge (Thermo 
Shandon cytospin4, Shandon Scientific Ltd., Cheshire, UK). The cells were 
adhered to microscope slides (Blue Star Micro Slides, West Midlands, UK) by 
centrifuging at 1000 rpm for 10 minutes. The slides were air-dried overnight 
and stained using a Quick III Haematology stain kit (Astral Diagnostics Inc., 
West Deptford, NJ, USA). The slides were fixed in methanol for 60 seconds 
then dipped sequentially into an eosin (eosinophilic staining) solution and 
azure solution (basophilic staining) for 60 seconds each. The slides were 
then rinsed with de-ionised water and allowed to air dry. They were examined 
by light microscopy (Carl Zeiss Ltd, Hertfordshire, UK) 200 cells were counted 
and the percentage of each cell type present recorded based on the 
assessment of at least 200 cells (see figure 2.1).
2.6 T-cell isolation
2.6.1 Magnetic column negative selection
Cells were re-suspended in 40pl of MACS buffer per 107 cells. Biotin antibody 
cocktail containing biotin conjugated anti - CD14, CD16, CD19, CD36, CD56, 
CD123, and CD235 (Miltenyi Biotech Ltd, Surrey, UK) was added (10^1/107 
cells) and the cells were incubated at 4°C for 10mins in the dark (see table 2.1). 
Following incubation a further 20pl per 106 cells of MACS buffer and 20pl/107 
cells of anti biotin antibody (Miltenyi Biotech Ltd, Surrey, UK) were added. The 
cells were incubated for a further 15mins at 4°C in the dark. Following incubation 
the cells were washed with 200pl MACS buffer then centrifuged at 1299 rpm 
(400xg) for 15min at 6°C. The cells were re-suspended in 500pl MACS buffer (at 
this point samples were taken for FACS analysis). The cells were passed 
through a mini MACS magnetic separator column (Miltenyi Biotech Ltd, Surrey, 
UK). The column was then washed (x3) with 500pl MACS buffer. All the effluent 
was collected and represented the enriched T-cell population. T-cell purity by
38
£h_
* <2*
T-
Figure 2.1 Cytospin preparation of peritoneal leukocytes showing lymphocytes 
(long arrows) and peritoneal macrophages (short arrows).
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this method was >85% as assessed by flow cytometric analysis of CD3+ 
lymphocytes (see Figure 2.2). The majority of “non-CD3+” contaminants were 
CD14+ Monocyte/Macrophages or CD19+ B-cells. T-cell purity and the nature of 
contaminating cells varied from patient to patient and may be a confounding 
factor when comparing in-vitro T-cell activation between patient groups. It 
should also be noted that though CD56 is a NK cell marker it is also expressed 
by a subset of activated T-cells which are thus depleted by the negative 
selection process.
Antigen Cells expressing antigen
CD14 Monocytes/Macrophages
CD16 Neutrophills/macrophages/NK cells
CD19 B-celIs/plasma cells
CD36 Platelets/RBC/Monocytes
CD56 NK cells/activated T-cells
CD123 Plasmacytoid DCs
CD235 RBC
Table 2.1 Cells depleted by the negative selection process
2.7 Isolation of BDCA-1 dendritic cells from blood
Peripheral blood mononuclear cells (PBMC) were isolated from 150ml of 
blood by ficol density gradient centrifugation. Cells were re-suspended in 
200pl of MACS buffer per 108 cells. One hundred pi of FcR blocking reagent 
(Miltenyi Biotech Ltd, Surrey, UK) was added per 108 cells. One hundred pi of 
CD19 (Miltenyi Biotech Ltd, Surrey, UK) micro beads per 108 total cells was 
added followed by 100pl of anti-BDCA-1-biotin antibody (Miltenyi Biotech Ltd, 
Surrey, UK) per 108 cells. The cells were then incubated for 15mins, washed 
in 20x labelling volume of MACS buffer and centrifuged for 12 mins at 1299 
rpm (400xg). The supernatant was removed completely and the cells re­
suspended in a final volume of 500pl/108 cells of MACS buffer. The cell 
suspension was passed down the magnetic separation column. The column
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Figure 2.2 Peritoneal T-cell magnetic column negative selection. PD effluent was 
collected from a timed overnight exchange and leukocytes were isolated by centrifugation. 
The non T-cell fraction were labelled with biotin conjugated anti-CD14, CD16, CD19, CD36, 
CD56, CD123, and CD235. Following incubation magnetically labelled anti-biotin antibody 
was added and the cells were passed through a mini MACS magnetic separator column 
(Miltenyi Biotec Ltd, Surrey, UK). To asses purity, cells were labelled with fluorescently 
conjugated monoclonal antibody directed against CD3. T-cell purity by this method was 
consistently >85% as assessed by flow cytometric analysis of CD3+ lymphocyte (see 
appendix for patient details).
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was rinsed (x3) with 500|jl of MACS buffer and the non-labelled, B-cell 
deplete fraction collected.
The B-cell depleted cell suspension was centrifuged for 12mins at 1299 rpm 
(400xg), the supernatant was removed completely and the cell pellet re­
suspended in 400pl of MACS buffer per 108 cells. On hundred pi of anti-biotin 
micro beads per 108 cells was added and the mixture was incubated for 
15mins at 6°C. Cells were washed in 5ml MACS buffer per 108 cells and 
centrifuged for 12mins at 1299rpm (400xg) and the supernatant removed 
completely. The cells were re-suspended in MACS buffer (500pl/108 cells) 
and passed down a magnetic separator column. The column was washed 
(x3) with 500pl of MACS buffer. The column was removed from the separator 
and the BDCA-1 positive cells removed by adding 1ml of MACS buffer and 
flushing it through the column with the plunger. Cells were washed (x3) with 
PBS.
2.8 Cell culture
2.8.1 T-cell culture
T-cells (isolated by MACS separation) were re-suspended (1x106 cells/ml) in 
RPMI 1640 (Sigma-Aldrich, Kent UK) containing 10% foetal calf serum 
(Hyclone-Perbio, Northumberland, UK), 2mM L-Glutamine (Gibco/invitrogen, 
Renfrewshire, UK), 100U/ml of Penicillin, 100pg/ml of Streptomycin (both from 
Gibco/lnvitrogen, Renfrewshire, UK) and 25 U/ml IL-2 (Roche, Mannheim 
Germany). Cells were cultured in U-bottomed 96 well plates (Sigma-Aldrich, 
Kent, UK) at 2x105 cells/well. The cells were incubated at 37‘C in a humidified 
incubator with 5% CO2.
2.8.2 Preparation of APC coated plates
APC coated plates were prepared by incubating unfractionated peritoneal 
leukocytes (0.25-2x106/ml) at 37*C in U-bottomed 96 well plates. After 1 hour, 
non-adherent cells were removed, counted and the number of adherent cells 
calculated (mean percentage adherence 35%, range 22-47% n=20). Flow
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cytometry performed pre- and post-adherence showed that adherent cells 
were derived from the cells in the monocyte/macrophage/DC gate (Figure 
2.3), however the exact phenotype of these adherent cells was not 
determined in these experiments.
2.8.3 Trans-well experiments
Trans-well experiments were performed using 24-well inserts, [pore size 
0.3pM] (BD Falcon 24-Multiwell Insert System, BD Biosciences, Oxfordshire, 
UK).
2.8.4 Mesothelial cell culture
Human peritoneal mesothelial cell isolation and culture was performed with 
the assistance of Dr. Ann Kift-Morgan (department of Medical Biochemistry 
and Immunology, Cardiff University) as previously described [82]. Briefly, 
omental tissue was collected from surgery in a sterile plastic receptacle 
containing approximately 50ml of sterile PBS solution and stored at 4'C. The 
tissue was gently manipulated to remove as much blood and unwanted 
surface material as possible. Twenty ml of freshly made trypsin-EDTA 
(Sigma-Aldrich Kent, UK; see 2.15) solution was aliquoted into 50ml tubes. 
Using two scalpels the tissue was dissected into pieces using a crossover 
motion. Each piece of tissue was placed into a tube with 20ml of trypsin- 
EDTA (0.25% trypsin, 0.1% EDTA) solution. The tube was sealed with a 
screw cap and placed on a rotating wheel (Stuart Scientific, Staffordshire, UK) 
in the 37'C incubator for 15 mins. The tubes were then centrifuged at 1600 
rpm (500xg) for 6 minutes at 15 C.
Meanwhile 20ml of trypsin-EDTA solution was aliquoted into the required 
number of tubes for the second digest. Tissue from the initial digest was 
transferred to the second digest tube and placed on rotating wheel in the 37°C 
incubator for a further 15 mins. The tubes were centrifuged at 1600 rpm 
(500xg) for 6 minutes at 15°C. Supernatant was carefully removed using a 
syringe and the bottom of the tube was tapped vigorously on the floor of the 
hood to loosen the pellet and make re-suspension easier and more efficient.
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Figure 2.3 Cells within the Monocyte/Macrophage/DC gate adhere to the cell culture 
well. Peritoneal leukocytes were collected from a timed overnight exchange by 
centrifugation. Leukocytes were incubated in 96 well tissue culture plates for 1h at 37’C. 
Non-adherent cells were removed by gentle aspiration. Cells were analysed by flow 
cytometry both pre and post adherence (percentage of total cells show; see appendix for 
patient demographics).
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Five ml of 10%v/v FCS supplemented M-199 (Gibco/lnvitrogen, Renfrewshire, 
UK) was added and rinsed around the tube to re-suspend and wash all the 
pelleted cells. The tubes were centrifuged at 1600 rpm (500xg) for 6 mins at 
15°C. The supernatants were removed and replaced with an appropriate 
volume of fresh 10% serum supplemented M-199. Cells were detached and 
re-suspended gently using a syringe. Five ml was syringed into a fresh T25 
culture bottle (Becton Dickinson, Oxfordshire, UK) and left to stand for 1 min. 
Cells were incubated at 37°C and observed frequently. After 1-2 days cells 
were pooled into a T75 flask (Becton Dickinson, Oxfordshire, UK). Medium 
was replaced every 3 days. Prior to transmigration assays HPMC from the 2° 
passage were transferred to 24 well plates and growth arrested as previously 
described [83]. Previous work in our lab has shown that mesothelial cell 
purity by this method is consistently >97% (with mesothelial cells identified by 
their unique cobblestone appearance, the presence of cytokeratin and the 
absence of factor VIII) [84, 85].
2.9 Flow cytometry
2.9.1 Preparation for fluorescence activated cell sorting analysis 
(FACS)
Prior to analysis, cells were re-suspended in PBS at 5 x 105 cells / 50pl. Fifty 
pi of cell suspension was added to individual wells of round-bottomed 96 well 
plates (BD Falcon, BD Biosciences, Oxfordshire, UK). Prior to flow cytometry, 
cells were incubated for 10 mins with 50pl blocking buffer containing 25% 
normal rabbit serum (DakoCytomation, Cambridgeshire, UK), 25% Human AB 
serum (HD supplies, Buckinghamshire, UK) and 50% PBS (to prevent non­
specific binding). Dilution experiments for all fluorochrome-conjugated 
antibodies were performed in order to determine optimal concentration for use 
in all subsequent assays. Following addition of antibody, the cells were 
incubated for 30 mins at 4°C in the dark. Cells were subsequently washed 
(x3) with PBS, then re-suspended in 250pl FACS buffer (section 2.15.2) in
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5ml round bottomed tubes (BD Falcon, BD Biosciences, Oxfordshire, UK) and 
analysed.
A Becton Dickinson FACS Calibur (Becton Dickinson, San Jose, CA, USA) 
was used to analyse the fluorescently labelled cells. T-cells were defined by 
their characteristic forward/side scatter profiles and by their co-expression of 
the T-cell marker CD3. Quadrant labels were placed on FACS plots so that 
99% of cells in the isotype control sample were within the lower left quadrant.
2.9.2 Isolation of T-regs by FACS
For mechanistic studies we defined T-regs as CD3+/CD4+CD25H| cells. This 
phenotype does not discriminate between T-regs and recently activated 
effector T-cells, however we were unable to utilise Foxp3 staining since this 
requires the cells to be fixed, permeabilsed and hence non-viable. Peritoneal 
T-cells were labelled with anti-CD3, CD4 and CD25 as per labelling protocol 
(section 2.9.1). A MoFlo high-speed cell sorter (DakoCytomation, Cambridge 
shire, UK) was used to isolate T-regs (CD3+/CD4+/CD25H|; Figure 2.4). Cells 
were sorted at between 5000 and 10,000 events per second and purity was 
assessed by re-analysing the sorted populations. Target cell purities >98% 
were achieved in every case.
2.10 Cell proliferation assays
2.10.1 3H-Thymidine incorporation
Following stimulation for 96h, stimulated cell cultures were incubated with 1 pi 
of 3H-Thymidine (37MBq/ml Amersham Biosciences Ltd, Buckinghamshire, 
UK) for 18hrs. The cells were then harvested onto filter plates using a cell 
harvester (Tomtec, Hamden, UK), and counts were analysed using a 
scintillation counter (Wallac, Turku, Finland).
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Figure 2.4 Isolation of peritoneal T-regs by fluorescence activated cell sorting 
analysis (FACS). PD effluent was collected from a timed overnight exchange and 
leukocytes were isolated by centrifugation. Cells were labelled with fluorescently conjugated 
anti-CD3, anti-CD4 and anti-CD25. Cells were sorted into T-regs and non-T-regs depending 
on their expression of CD25.
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2.10.2 CFSE Labelling of T-cells
T-cells were suspended in PBS to a final concentration of 0.5x106 cells/ml. A 
5mM stock solution of CFSE in DMSO (Gibco/lnvitrogen, Renfrewshire, UK) 
was prepared. This solution was added to the cells to make a final 
concentration of 3pM. Cells were subsequently incubated in the dark for 10 
mins at 37°C. FCS was added to a final concentration of 10%v/v and cultures 
further incubated for 5 mins at room temperature. Five volumes of ice-cold 
FCS were added to quench staining and the cells were washed (x3) with PBS. 
The cells were subsequently cultured and stimulated. CFSE labelling was 
analysed by flow cytometry (CFSE detected in the FL-1 channel).
2.11 Detection of apoptosis and T-cell viability
Cell viability was assessed by using propidium iodide (PI) staining 
(Calbiochem, San Diego, USA). Prior to analysis, cells were re-suspended in 
100pl of PBS (1x106 cells/ml). Two pi of PI was added to the cell suspension 
and PI staining was detected in the FL-3 channel (figure 2.5A).
T-cell apoptosis was assessed with the Annexin V apoptosis detection kit 
(Calbiochem, San Diego, Ca, USA) [86], Cells were washed with PBS (x3) 
and re-suspended in 100pl (1x106 cells/ml) of binding buffer (Calbiochem, 
San Diego, Ca,USA). Subsequently 1.25pl of Annexin V-FITC was added to 
each well for 10 mins. Cells were washed with PBS (x3) then analysed by 
flow cytometry (Figure 2.5B).
2.12 Cytokine detection assays
2.12.1 Intracellular flow cytometry
To stimulate cytokine production, cells were stimulated with Phorbol Myristate 
Acetate (PMA, 500ng/ml) and lonomycin (50ng/ml) (both from Sigma St Louis, 
Mo, USA) in the presence of monensin (2pM) (eBiosceience, San Diego, Ca,
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Figure 2.5 Assessment of peritoneal leukocyte viability (A) T-cells were isolated from 
overnight PD effluent by magnetic column negative selection. T-cells were re-suspended in 
100 pi PBS (1x106 cells/ml). Two pi of Propidium Iodide was added and cells were analysed 
by flow cytometry (gates set according to isotype control). (B) Peritoneal T-cells were 
isolated by magnetic column negative separation. Cells were stimulated with increasing 
concentrations of PHA. Following 24h of stimulation, cells were stained with fluorescently 
labelled monoclonal antibody directed against CD3 and Annexin V. A combined gate was 
set on T-cells based on their CD3 and FSC:SSC profiles. (Numbers indicate the percentage 
of CD3+ T-cells expressing Annexin V; see appendix for patient demographics)
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USA) for 4h at 37 C. Cells were then stained for surface marker expression 
(following the FACS staining protocol above). After washing in PBS (x3) cells 
were incubated in 100pl fixation/permeabilisation buffer (eBiosceience, San 
Diego, Ca, USA) for 30 mins at 4°C in the dark. Cells were subsequently 
washed (x3) with permeabilisation buffer (eBiosceience, San Diego, Ca, USA), 
and then re-suspended in 50pl of permeabilisation buffer containing optimal 
concentrations of fluorochrome-conjugated antibody (Table 2.1). Cells were 
incubated with antibody for 30 mins at 4°C in the dark, then washed (x3) with 
permeabilisation buffer, re-suspended in 200pl of PBS and analysed by flow 
cytometry (FACS Calibur, BD Biosciences, Oxfordshire, UK). It should be 
noted that the degree of cell permeabilisation achieved with this technique was 
not assessed. Consequently some differences in intracellular staining may 
reflect differences in the adequacy of permeabilisation rather than changes in 
cytokine production.
2.12.2 ELISpot assay
Anti human IFN-y antibody (Mabtech, Dorset, UK) was diluted in PBS to a 
final concentration of 10pg/ml. Fifty pi was added to each well of an ELISpot 
plate (Millipore, Hertfordshire, UK). Plates were incubated at 37°C for 3h then 
washed (x5) with PBS. One hundred pi of FCS-RPMI (section 2.15.6) was 
added to each well for 1 hour at room temperature as a blocking step. 
Blocking media was discarded and the responder cells (either PBMC or 
peritoneal leukocytes) were added to the wells in 50pl FCS-RPMI (2x105 cells 
per well). A further 50pl of FCS-RPMI containing 10pg/ml of either purified 
protein derivative (PPD), Tetanus toxoid (TT) or Haemaglutinin (HA) were 
added to each well (control wells that did not require peptide received 50pl of 
the media alone). Plates were then wrapped in foil and incubated at 37 C 
for 18h. Following incubation, wells were washed (x5) with PBS to remove 
non-adherent cells. Adherent cells were lysed by the addition of distilled 
water (100 pi /well for 10 mins at room temperature).
The biotinylated secondary antibody 7-B6-1-Biotin (Mabtech, Dorset, UK) was 
diluted 1:1000 in PBS and 50pl was added to each well. Plates were
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subsequently placed in the dark room for 2h at room temperature. The plates 
were then washed x5 with PBS and 50pl of Streptavadin-Alkaline 
phosphatase (Bio-Rad, Hertfordshire, UK) (diluted 1:1000 with PBS) was 
added to each well. Plates were subsequently placed in the dark room for 2h 
at room temperature. Fifty pi of developing solution (Bio-Rad, Hertfordshire, 
UK) was added to each well and plates were left to develop in the dark for a 
minimum of 15 mins until the spots were clearly visible. The plates were 
washed (x5) with tap water to stop the reaction. Plates were then air-dried in 
the dark before the spots were counted.
2.12.3 Multiplex bead-based cytokine assay
Cytokine levels were analysed using the Bio-Plex cytokine assay system as 
per manufacturer’s instructions (Bio-Rad, Hertfordshire, UK). Wells were pre­
wetted with Bio-Plex assay buffer (Bio-Rad, Hertfordshire, UK). Buffer was 
removed by vacuum filtration. A working solution of multiplex beads (Bio-Rad, 
Hertfordshire, UK) was prepared by adding 240pl of stock bead solution to 
2800pl of Bio-Plex assay buffer. Fifty pi of multiplex bead working solution 
was added to each well and buffer was removed by vacuum filtration. Each 
well was washed twice with Bio-Plex wash buffer (Bio-Rad, Hertfordshire, UK) 
and 50pl of the PD effluent to be analysed was added to each well. Plates 
were covered with sealant tape (Bio-Rad, Hertfordshire, UK) and aluminium 
foil, then left to incubate for 30 mins at room temperature. Wells were washed 
with Bio-Plex wash buffer (x3) and 25pl of detection antibody (Bio-Rad, 
Hertfordshire, UK) was added to each well. Plates were covered with sealant 
tape and aluminium foil then incubated at room temperature for a further 30 
mins. Wells were further washed (x3) and 50pl of Streptavadin PE (Bio-Rad, 
Hertfordshire, UK) was added to each well. Plates were covered with sealant 
tape and aluminium foil then incubated at room temperature for 10 minutes 
followed by washing (x3) with 100pl of wash buffer. Beads were re­
suspended in 125pl of Bio-Plex assay buffer (Bio-Rad, Hertfordshire, UK) and 
the plate was read on the Bio-Plex array reader.
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2.13 Single telomere length analysis (STELA)
STELA (Single telomere length analysis) was performed on our behalf by Dr. 
Duncan Baird, Department of Pathology, School of Medicine, Cardiff 
University. This PCR based technique allows the accurate measurement of 
single telomere molecules. The methodology is described in detail elsewhere 
[87, 88].
2.14 Statistical analysis
Statistical analysis was carried out using the SPSS statistical programme 
(SPSS for Mac, Rel. 10.0.0. 1999. Chicago: SPSS Inc). Differences between 
experimental groups were tested non-parametrically with the Mann Whitney or 
Kruksal Wallis test for unpaired samples and the Wilcoxan Signed Ranks test 
for paired samples. In proliferation studies, the mean was analysed using 
repeated measures analysis of variance. A p value of less than 0.05 was 
considered statistically significant.
2.15 Reagents
2.15.1 RBC Lysis buffer
155mM Ammonium Chloride (4.145g), 7mM Potassium Carbonate (0.48g), 
0.1 mM EDTA (0.0185g) (Gibco/lnvitrogen Ltd., Renfrewshire UK) were 
dissolved in 500ml distilled water at pH 7.2 and stored at 4°C.
2.15.2 FACS buffer
10mM EDTA (1.85g), 15mM Sodium Azide (0.05g) (Fisher Scientific UK, 
Leicestershire, UK) and 1% w/v Bovine Serum Albumin (BSA) (5g) (Fisher 
Scientific UK, Leicestershire, UK) dissolved in 500ml PBS at pH 7.3 and 
stored at 4°C.
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2.15.3 MACS buffer
EDTA 2mM (0.372g), 1%w/v BSA (5g) dissolved in 500ml PBS and stored at 
4°C.
2.15.4 EDTA free MACS buffer
1% BSA (5g) dissolved in 500ml PBS and stored at 4°C.
2.15.5 Trypsin -  EDTA Solution
5 mis of x10 Trypsin -  EDTA stock solution (Sigma-Aldrich, Kent, UK) was 
added to 45ml of sterile PBS
2.15.6 FCS-RPMI
50mls of FCS was added to 450mls of RPMI.
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2.16 Soluble mediators and blocking antibodies
Supplier
lnterleukin-2 Roche, Hertfordshire, UK
lnterleukin-6 BD Pharmingen, Oxfordshire, UK
Soluble gp130 R&D Systems, Oxfordshire, UK
HMB-PP A gift from Dr. Armin Reichenberg Universitats 
kiinikum Giessen und Marburg I nstitut fur Klinische 
Chemie und Pathobiochemie Gaffkystrasse, 
Giessen, Germany
Anti-TGFp R&D Systems, Oxfordshire, UK
Anti-IL-10 R&D Systems, Oxfordshire, UK
Concanavalin A Sigma-Aldrich, Kent, UK
OKT3 (anti-CD3) A gift from Dr E.C. Wang, Cardiff University 
Department of Medical Biochemistry and 
Immunology.
Table 2.2 Soluble mediators and blocking antibodies
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Antibody Supplier Clone Isotope Dilution
FITC mouse IgG 
isotype
eBioscience, San Diego, USA P3 igGl 1:50
PE mouse IgG 
isotype
BD pharmingen, Oxfordshire, UK MOPC-21 igGi 1:100
APC mouse IgG 
isotype
eBioscience, San Diego, USA P3 IgGl 1:25
PE-CY5.5 mous 
IgG isotype
eBioscience, San Diego, USA P2 lgG2a 1:100
CD25 APC eBioscience, San Diego, USA BC96 lgG1 1:25
CD69 FITC BD pharmingen, Oxfordshire, UK FN50 IgGl 1:100
IL-6R PE BD pharmingen, Oxfordshire, UK 
San Diego, Ca
M5 IgGl 1:100
CCR5 FITC BD pharmingen, Oxfordshire, UK 2D7/CCR5 lgG2a 1:100
CXCR3 PE BD pharmingen, Oxfordshire, UK IC6/CXCR3 lgG1 1:50
CD8 PE DakoCytomation, Cambridgeshire, 
UK
DK25 lgG1 1:100
CD4Cy5.5 Caltag Labs San Francisco, Ca 2212 lgG2a 1:250
CD127
(IL-7R)
eBioscience, San Diego, USA eBioRDR5 lgG1
CD45R0 FITC BD pharmingen, Oxfordshire, UK UCHL1 MslgG2a 1:50
CXCR1 PE BD pharmingen, Oxfordshire, UK 42705.111 lgG2a 1:100
CD3 PE BD pharmingen, Oxfordshire, UK UCHT1 lgG1 1:100
CD14 FITC BD pharmingen, Oxfordshire, UK M5E2 lgG2a 1:50
Foxp3 FITC eBioscience, San Diego,USA 236A/E7 lgG1 1:50
IFN-y PE eBioscience, San Diego,USA 4S.B3 lgG1 1:100
IL-4 PE eBioscience, San Diego,USA 8D4-8 IgGl 1:50
Vy9 FITC Immunotech A Coulter Company 1463 Lot 17 IgGl 1:100
Vy9 Cy5.5 Immunotech A Coulter 4G IgGl 1:250
TCRVp IO test, BetaMark, Beckman 
Coulter, High Wycombe,UK).
1:10
Table 2.3 Fluorochrome conjugated antibodies.
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Chapter 3
Peritoneal T-cells: Phenotype, Activation Status, 
Proliferation and Cytokine Production
56
3.1 Introduction
Peritonitis remains a major cause of morbidity in patients on PD. Many 
patients suffer only a single episode in the early years of treatment, but in 
some patients there is relapse or frequent recurrence. Degree of severity is 
linked to the pathogenesis of the organism as well as the source of infection. 
Incidence and severity have also been linked to detrimental structural and 
functional changes of the peritoneal membrane [8, 9, 12]. Over the past 20 
years our understanding of the peritoneal inflammatory process has increased 
significantly. The vast majority of these studies have focused on the 
contribution of either the peritoneal macrophage or the peritoneal mesothelial 
cell in regulating inflammatory processes. Despite representing up to 25% of 
the resident peritoneal leukocyte population and forming a significant 
proportion of the cell population in resolving peritonitis, the role of peritoneal 
T-cells has received significantly less attention [33-41].
Previous studies have suggested that resident peritoneal T-cells display an 
activated phenotype characterised by increased expression of CD69, CD25 
and HLA-DR. This “increased activation” has been interpreted differently by 
different authors with some suggesting that the T-cells are “primed” for 
subsequent activation whilst others have suggested that they may be in a 
hypo-responsive state [29-33]. Similarly, although some have suggested that 
peritoneal T-cells are unlikely to proliferate following activation, this has yet to 
be been formally assessed in-vitro [89].
We now have evidence from the mouse model of peritonitis [Topley, Jones, 
unpublished data] to suggest that T-cell activation is a pivotal event in the 
acute response, the transition from innate to adaptive immunity and immuno- 
resolution. It is also apparent that T-cell dysregulation is one of the triggers 
that drive chronic inflammation in the mouse peritoneum. In light of these 
findings it is essential that we gain a better understanding of the role of human 
T-cells in the peritoneal inflammatory pathways and inflammation induced 
membrane damage.
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The specific aims of this chapter are to:-
a) Define the basic phenotype (including activation status) of resting 
peritoneal T-cells.
b) Determine the cytokine profile of peritoneal T-cells (TH1/TH2 balance).
c) Asses the proliferative capacity of peritoneal T-cells following 
stimulation.
3.2 Results
3.2.1 Peritoneal lymphocytes - basic phenotype
Based on data from leukocytes isolated from 20 stable (non-infected) patients, 
lymphocytes represent 18 (±5.4%) of the total peritoneal leukocyte population 
in patients on PD. Within this peritoneal lymphocyte population the vast 
majority of the cells are CD3 positive (mean 88±8%). This group of T-cells 
can be further sub-divided into CD4 positive (mean 36±3%) and CD8 positive 
(mean 44±2.66%). A representative flow cytometry scatter plot is shown in 
Figure 3.1.
3.2.2 Peritoneal T-cell activation status
In order to quantitate the proportion of activated T-cells, we analysed the 
expression of CD69 (an early activation marker) and CD25 (a late activation 
marker) on both peripheral blood and peritoneal T-cells isolated from stable 
(no infection in the last 3 months) patients on PD.
The results show that when compared to peripheral blood T-cells, peritoneal 
T-cells express much higher levels of CD69 (Figure 3.2A) and marginally 
higher levels of CD25 (Figure 3.2B). The precise mechanism responsible for
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Figure 3.1 Basic phenotype of peritoneal T-cells. Peritoneal leukocytes were isolated 
from overnight PD effluent. Cells were labeled with fluorescently labeled monoclonal 
antibody directed against CD3, CD4 and CD8. A gate was set on lymphocytes according 
to their characteristic FSC:SSC profile. The percentage of CD3+ cells within the 
lymphocyte gate is shown. A further gate was set on CD3+ cells and the percentage of 
CD4+/CD8+ cells within this gate was calculated. Representative example shown from 20 
separate patients (see appendix for patient demographics).
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Figure 3.2. Expression of cell surface activation markers on peritoneal and 
peripheral blood T-cells. Paired samples of peripheral blood and peritoneal leukocytes 
were collected from PD patients. Cells were labeled with fluorescently conjugated 
monoclonal antibody directed against CD3, CD69 and CD25. A combined gate was set T- 
cells based on their FSC:SSC profiles and their expression of CD3. Results show the 
percentage of CD3+ cells expressing CD69(A) or CD25(B). Horizontal lines represent the 
mean. Differences between groups were tested using the Wilcoxan signed ranks test (see 
appendix for patient demographics).
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this apparent local T-cell “activation” in the dialysed peritoneum have not been 
identified. We speculated that it was related either to exposure to PD solutions 
or that the process of transmigration into the peritoneal cavity results in 
peritoneal T-cell activation.
To assess the impact of PD fluid on T-cell activation status, peripheral blood 
T-cells were cultured overnight in the presence of either Dianeal® (1.36% 
anhydrous glucose) or Extraneal® (7.5% icodextrin). As shown in Figure 
3.3A, this did not, however, result in any significant up-regulation of activation 
markers.
To determine whether changes in T-cell phenotype were induced by the 
transmigration process, we utilised a validated transmigration chamber 
system. A mesothelial monolayer was formed on the underside of a trans-well 
insert [83] (Figure 3.3B). As shown in Figure 3.3C, the transmigration of 
PBMC across this cytokine stimulated mesothelial monolayer did not result in 
any significant up-regulation of CD69 expression on CD3 positive cell 
population.
3.2.3 Polyclonal stimulation of peritoneal T-cell
Given that peritoneal T-cells already display an activated phenotype, some 
authors have suggested that these cells may be “anergic” and therefore 
resistant to further stimulation [90]. To ascertain whether peritoneal T-cells 
have the capacity to respond to stimulation, isolated CD3+ peritoneal T-cells 
from stable PD patients were cultured overnight in the presence of optimal 
concentrations of Phytohemagglutinin (PHA), a polyclonal T-cell activator. As 
demonstrated in Figure 3.4, stimulation of peritoneal T-cells with PHA results 
in increased expression of both CD69 and CD25 suggesting that these T-cells 
can indeed be further activated (in-vitro).
3.2.4 TH1 vs. TH2 polarisation
TH1/TH2 polarisation of T-cells is evidenced by the production of IFN-y and 
IL-4 respectively. In an attempt to define the TH1/TH2 profile of resident
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Figure 3.3. Exploring possible mechanisms of T-cell activation (A) PBMC were 
isolated from the blood of healthy volunteers (n=5) by ficoll density gradient centrifugation. 
PBMC were cultured overnight in the presence of culture medium alone, PHA, extraneal 
(diluted 1:2) or dianeal (diluted 1:2). T-cell activation (defined as increased expression of 
CD69 and CD25) was assessed by flow cytometry at 24, 48 and 72h (data at 48h shown 
as a representative example). (B) A mesothelial monolayer was formed on the underside 
of a tran-swell insert. Mesothelial cells were stimulated for 24h with IL-1 (50pg/ml), then 
washed. PBMC (isolated from the blood of 5 healthy volunteers by ficoll density gradient 
centrifugation) were placed in the upper chamber of the trans-well. (C) Samples were 
taken from the upper and lower chambers at 24hrs. T-cells were labeled with fluorescently 
conjugated monoclonal antibody directed against CD3 and CD69. A combined gate was 
set T-cells based on CD3 expression and their FSC:SSC profiles. Results show the 
percentage of CD3+ cells expressing CD69 (horizontal line represents mean).
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CD69
Figure 3.4 Activation of peritoneal T-cells with Phytohemagglutinin(PHA).
Peritoneal leukocytes were collected on ice from a timed overnight exchange. 
Leukocytes were stimulated with PHA (10|jg/ml) for 12h. T-cells were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3, CD69 and CD25. A 
combined gate was set T-cells based on CD3 expression and their FSC:SSC profiles. 
The percentage of T-cells expressing CD25, CD69 or both was calculated. 
Representative example shown from 5 separate donors (see appendix for patient 
demographics).
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peritoneal T-cells, we utilised intracellular flow cytometry, to assess cytokine 
production at a single cell level. As shown in Figure 3.5, the majority of 
isolated CD3+ peritoneal T-cells were polarised towards a TH1 type response 
characterised by the capacity to produce IFN-y with very few peritoneal T-cells 
producing IL-4. When PD effluent obtained during peritonitis was analysed 
using Luminex array technology, increased levels of IFN-y were detected but 
only very low levels of IL-4, suggesting that the in vivo response during 
infection is also apparently skewed toward a TH1 phenotype.
3.2.5 Proliferation of peripheral blood and peritoneal T-cells isolated 
from stable PD patients
In order to reproducibly and accurately quantify proliferation, T-cells from the 
peripheral blood and the peritoneum of stable PD patients were isolated by 
negative selection using magnetic beads (see Materials and Methods, section 
2.6.1). Isolated T-cells were then stimulated with the T-cell specific mitogen 
OKT3 (anti-CD3). When isolated peripheral blood T-cells from stable PD 
patients (no infection in the past 3 months) were stimulated with OKT3 (0- 
100ng/ml) there was a dose dependant increase in proliferation (Figure 3.6A). 
Peritoneal T-cells isolated from the same patients had negligible proliferation 
in response to OKT3 (Figure 3.6A). To confirm this lack of response, 
peritoneal T-cell proliferation experiments were also performed with a range of 
alternative mitogenic stimuli including OKT3 coated plates, Concanavalin A 
and a combination of anti-CD3 and anti-CD28. None of these stimuli were 
able to induce the proliferation of peritoneal T-cells (data not shown).
To ascertain whether the non-proliferating cells were being activated, isolated 
peritoneal T-cells from these same donors were examined for their expression 
of CD69. OKT3 treatment resulted in a dose dependant increase in CD69 
expression in all patients examined suggesting that these cells are indeed 
capable of being activated but are not able to proliferate in response to 
mitogenic stimulation (Figure 3.6B).
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Figure 3.5 TH1 vs. TH2 polarisation of peritoneal T-cells. Peritoneal leukocytes 
(5x105/well) were stimulated with PMA (500ng/ml)/ lonomycin (50ng/ml) for 4 hours in the 
presence of monensin (2pM). Cells were labeled with fluorescently conjugated 
monoclonal antibody directed against CD3. Cells were subsequently fixed, permeabilized 
then stained with fluorescently labeled anti-IFN-y or anti-IL-4. A combined gate was set 
on peritoneal T-cells based on their FSC:SSC profiles and their CD3 expression. The 
percentage of IFN-y+ or IL-4+ T-cells was calculated. (A) Representative FACS plot. (B) 
Intracellular Flow cytometry data from 8 separate patients (results shown as % of CD3+ 
T-cells expressing either IFN-y or IL-4; the horizontal line represents the mean values) 
.(C) Serial samples of peritoneal effluent was collected from patients suffering from acute 
peritonitis. IL-4 and IFN-y levels were analysed with a multiplex bead-based cytokine 
assay. (Results show mean ±SE of 10 separate patients; see appendix for patient 
demographics).
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Figure 3.6 OKT3 stimulation of peritoneal and peripheral blood T-cells. (A) Peripheral 
blood and peritoneal T-cells were isolated from peritoneal dialysis patients by magnetic 
column negative separation. Isolated T-cells were stimulated with increasing 
concentrations of OKT3 (0-100ng/ml) in the presence of IL-2 (25U/ml). Proliferation (3H- 
Thymidine incorporation) was assessed at 96h. Proliferation results show mean ± SE of 
duplicate cultures (representative example shown from 6 separate donors). (B) Magnetic 
column isolated peritoneal T-cells were stimulated for 4 hours with OKT3 (10ng/ml). Cells 
were stained with fluorescently labeled monoclonal antibody directed against CD69. A gate 
was set on T-cells based on their FSC/SSC profile. Results show the percentage of T-cells 
expressing CD69 (see appendix for patient demographics).
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3.2.6 The role of antigen presenting cells (APC) in T-cell activation
T-cell proliferation in-vivo is triggered when a T-cell recognises the antigen: 
MHC class II complex presented on the surface of antigen presenting cells 
(APC). As well as antigen presentation, the APC provide co-stimulation in the 
form cell surface molecules (such as CD80 and CD86) [91]. In view of this, 
we elected to examine whether accessory cells are required to drive the in- 
vitro proliferation of peritoneal T-cells.
Initially we examined the proliferative response of CD3+ peritoneal T-cells co­
stimulated in the presence of other peritoneal leukocyte populations. These 
initial experiments used the whole (i.e. unfractionated) peritoneal leukocyte 
population (from stable PD patients). Following culture (see Materials and 
Methods, section 2.8) peritoneal leukocyte were stimulated with OKT3 (0- 
100ng/ml). This resulted in a dose dependant increase in proliferation, 
suggesting that peritoneal T-cells do in fact have the capacity to proliferate but 
that they require co-stimulation with antigen presenting or accessory cells. To 
confirm the specificity of this APC-dependency, peritoneal T-cells were 
stimulated on culture plates pre-coated with peritoneal APC (see Materials 
and Methods, section 2.8.2). Under these conditions significant APC- 
dependent proliferation of peritoneal T-cell was observed (Figure 3.7B).
To further strengthen this observation, (in a single experiment) we stimulated 
peritoneal T-cells in the presence of allogenic peripheral blood dendritic cells. 
Again, significant peritoneal T-cell proliferation was observed (Figure 3.7C). 
Control experiments revealed that when cultured alone; neither T-cells nor DC 
underwent any significant proliferation.
Subsequent experiments utilising CFSE staining suggested that it was indeed 
the peritoneal T-cell population that was specifically proliferating in these 
experiments (Figure 3.7D). It is apparent from Figure 3.7D that the CFSE 
staining pattern of proliferating peritoneal T-cells is atypical in that there is a 
general shift of the whole population to the left in contrast to the well defined 
peaks typically seen with proliferating PBMC. The reasons for this are not 
clear, since the methodology has previously been validated in PBMC
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Figure 3.7 The role of antigen presenting cells (APC) in peritoneal T-cell 
proliferation. (A) Peritoneal leukocytes were isolated from overnight PD effluent. The 
unfractionated leukocytes were stimulated with increasing concentrations of OKT3 (0- 
50ng/ml). Proliferation (3H-Thymidine incorporation) was assessed at 96h (results show 
mean ± SE of 3 separate experiments). (B) APC coated plates were prepared by 
adhering peritoneal leukocytes to 96-well plates for 1 hour then removing non-adherent 
leukocytes. Isolated peritoneal T-cells were stimulated with OKT3 in the presence of 
increasing numbers of APC. Proliferation (3H-Thymidine incorporation) was assessed at 
96h (proliferation results show mean ±SE of duplicate cultures). Means were analysed 
using repeated measures analysis of variance. (C) Blood derived BDCA-1+ myeloid 
dendritic cells (MDC) were isolated from peripheral blood by 2-stage magnetic 
separation. Peritoneal T-cells were isolated from overnight PD effluent by magnetic 
column negative separation. Peritoneal T-cells were stimulated with OKT3 in the 
presence of allogenic peripheral blood MDC(T:cell to MDC ratio 5:1). Proliferation (3H- 
Thymidine incorporation) was assessed at 96h. (D) Peritoneal T-cells were labeled with 
CFSE then stimulated with OKT3(10ng/ml) in the presence or absence of allogenic 
APC. CFSE fluorescence within the gated T-cell population was analysed by flow 
cytometry at day 7 (see appendix for patient demographics).
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experiments. It may reflect an increased susceptibility of peritoneal T-cells to 
CFSE induced cell death..
3.2.7 The role of cell-cell contact and IL-6 in peritoneal T-cell 
proliferation
To establish the mechanism by which accessory cells promote peritoneal T- 
cell proliferation, these cells were co-cultured with peritoneal APC in a trans­
well insert system (which permits transport of soluble factors but prevents 
direct cell-cell contact). These experiments determined that for maximal 
peritoneal T-cell proliferation direct cell-cell contact was required, although 
soluble factors also increased proliferation (albeit to a much lesser extent) 
(Figure 3.8).
Given that IL-6 is known to be pivotal mediator of the peritoneal immune 
response, we speculated that this pleiotropic cytokine might be one of the 
soluble factors influencing T-cell proliferation [50]. IL-6 exerts its effects via 
binding to the membrane bound IL-6 receptor, however it can also bind a 
soluble IL-6 receptor (slL-6R), forming a ligand-receptor complex. The sIL- 
6R/IL-6 complex can activate cells that lack the cognate IL-6R by binding to 
the ubiquitously expressed signal transducing element gp130 (IL-6 trans­
signalling) [46, 47, 50-52]. To investigate the role of IL-6 signalling in 
regulating peritoneal T-cell proliferation, the cells were stimulated with 
increasing concentrations of IL-6 or increasing concentrations of soluble 
gp130 (which blocks IL-6 trans-signalling). In these limited number of 
experiments, IL-6 did not appear to have a significant impact on peritoneal T- 
cell proliferation (Figure 3.9A.B).
3.2.8 T-cell proliferation during peritonitis
We next speculated that effector T-cells recruited into the peritoneum during 
peritonitis might behave differently to resident peritoneal T-cells present 
during the steady (non-infected) state. To address this question peritoneal T- 
cells were isolated from patients during acute peritonitis episodes and 
stimulated in the presence or absence of peritoneal APC. In contrast to 
peritoneal T-cells isolated from stable PD patients, peritoneal T-cells isolated
69
ASoluble
mediators
Trans-well insert
T-cells
Porous membrane (0.4|jm)
APC (DC, Monocytes, Macrophages)
B
20 n
o'5 
2 o
Q.
8 ®
.E x
I I  10
■a o
E>»
P=0.01
0 - ■fer
T-cell 
(no APC)
APC:T-Cell
(across
tran-swell
insert)
APC:T-cell 
(in direct 
contact)
♦ patient B3
■ patient A1
A patient A4
□ patient B3
X patient A5
Figure 3.8. The impact of cell-cell contact on peritoneal T-cell proliferation.
Peritoneal T-cells were isolated from overnight PD effluent by magnetic column negative 
separation. APC coated plates were prepared by adhering allogenic peritoneal 
leukocytes to plates for 1 hour then removing non-adherent leukocytes. (A) Trans-well 
inserts were used to prevent direct cell-cell contact between APC and T-cells. (B) 
Peritoneal T-cells were cultured (in duplicate) in medium alone, in direct contact with 
APC or with APC on the opposite side of the tran-swell insert membrane. Mean 
proliferation (3H-Thymidine incorporation) was assessed at 96h. Means were analysed 
using repeated measures analysis of variance.
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Figure 3.9 The impact of IL-6 signalling on peritoneal T-cell proliferation. Peritoneal 
T-cells were isolated from overnight PD effluent by magnetic column negative separation. 
APC coated plates were prepared by adhering allogenic peritoneal leukocytes to plates 
for 1 hour then removing non-adherent leukocytes. (A) Peritoneal T-cells were cultured in 
the presence of APC and increasing concentrations of IL-6 or (B) increasing 
concentrations of soluble gp130 (sgp130). Proliferation (3H-Thymidine incorporation) was 
assessed at 96h. Results show mean ±SE of duplicate cultures (see appendix for 
patient demographic).
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during acute peritonitis are able to proliferate in the absence of APC and, in 
fact allogenic peritoneal APC down-regulate the proliferation of these cells 
(Figure 3.10A).
3.2.9 Apoptosis of recruited T-cells
To establish the mechanism whereby APC down regulate recruited T-cell 
proliferation we analysed the expression of the early apoptosis marker 
Annexin V. As shown in Figure 3.1 OB, stimulation of recruited peritoneal T- 
cells in the presence of APC resulted in increased expression of Annexin V, 
suggesting that these cells were undergoing apoptosis.
3.3 Discussion
To date, the phenotype, function and regulation of human peripheral tissue T- 
cells have remained poorly defined. The lack of readily available samples 
(especially during the “non-inflamed” state) means that we are heavily reliant 
on data extrapolated from peripheral blood cells or from animal models. 
Though the basic surface phenotype of peritoneal T-cells has been previously 
documented, a more detailed functional analysis of this leukocyte population 
remains to be defined [29-33]. In view of the potential importance of T-cells in 
regulating peritoneal immune function and host defence, we undertook a more 
detailed functional analysis of the resident peritoneal T-cell population 
focussing in particular on their activation status, cytokine profile and 
proliferative capacity.
In agreement with previous studies we have shown that, as compared to 
peripheral blood, the peritoneal T-cells from patients on PD express 
significantly increased levels of CD69 (a very early marker of T-cell activation 
[92]. This suggests that peritoneal T-cells may be more “activated” than 
peripheral blood T-cells. In trying to delineate the mechanisms that lead to 
this increased CD69 expression, we performed a series of experiments 
attempting to mimic some of the factors that contribute to the unique intra-
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Figure 3.10 Proliferation of peritoneal T-cells collected during bacterial peritonitis.
(A) Timed overnight PD effluent was collected from patients suffering from acute 
bacterial peritonitis (day 4). Peritoneal T-cells were isolated by magnetic column 
negative separation. APC coated plates were prepared by adhering allogenic peritoneal 
leukocytes to plates for 1 hour then removing non-adherent leukocytes. Cells were 
stimulated with OKT3(10ng/ml). Proliferation (3H-Thymidine incorporation) was assessed 
at 96h (proliferation results show mean ±SE of duplicate cultures). Means were 
analysed using repeated measures analysis of variance. (B) Overnight PD effluent was 
collected from patients suffering from acute bacterial peritonitis (day 4). Peritoneal T- 
cells were isolated by magnetic column negative separation. APC coated plates were 
prepared by adhering allogenic peritoneal leukocytes to plates for 1 hour then removing 
non-adherent leukocytes. Cells were stimulated with OKT3. Following 48h of stimulation, 
cells were stained with fluorescently labeled monoclonal antibody directed against CD3 
and Annexin V. A combined gate was set on T-cells based on their CD3 and FSC:SSC 
profiles. Results show the percentage of CD3+ T-cells expressing Annexin V  (see 
appendix for demographics, peritonitis episode and microbiology data).
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peritoneal environment. Neither in vitro exposure of PBMC to unused PD 
solutions, nor transmigration across a mesothelial monolayer resulted in 
significant up-regulation of CD69 on peripheral blood T-cells. Clearly these in 
vitro experiments are limited in that they do not mimic the sophisticated 
cytokine/cellular milieu of the human peritoneal cavity. They are also limited 
by the absence of an adequate positive control showing that the 
transmigrated cells are capable of up-regulating CD69 expression. In spite of 
this, the findings suggest that other mechanisms may be responsible for the 
increased "activation” of these cells.
Interestingly, the number of CD69+ T-cells was much higher than the number 
of CD25+ cells, and only a few cells (<10%) were CD25/CD69 double positive. 
This was unexpected, since both CD25 and CD69 are markers of T-cell 
activation and in vitro stimulation of peritoneal T-cells with mitogens leads to 
increased expression of both molecules [93]. There are two possible 
explanations for this. The first explanation lies in the differing temporal 
expression profiles of these markers. CD25 is a “late” activation marker and 
requires a more sustained period of TCR stimulation than does CD69 [93]. 
The putative in vivo stimulus leading to CD69 up-regulation may be transient 
and incomplete and hence insufficient to increase CD25 expression 
(moreover, many of the CD25+ cells may be T-regs rather than activated T- 
cells -  see Chapter 4, section 4.2.6). Accordingly, the CD69+ cells are in 
effect “partially activated” and may be resistant to further stimulation. 
Analogous to this, peripheral blood T-cells from Lupus Nephritis patients show 
an increased expression of CD69, but are hypo-responsive to further 
stimulation. Additionally, human synovial fluid T-cells display hypo- 
responsiveness that parallels their CD69 expression [89, 94-96].
The alternative explanation is that CD69 expression may not only signify T- 
cell activation; it may delineate a distinct T-cell subset with unique effector 
functions. The evidence supporting this comes from a series of experiments 
analysing the pathogenesis of collagen-induced arthritis (CIA). Rather 
unexpectedly, it was shown that CD69 deficient mice developed an 
exacerbated form of disease associated with a hyper-immune response and
74
decreased levels of TGFp. Together with similar observations in the NK- 
sensitive tumor model these findings have revealed a novel regulatory/ 
suppressive role for CD69 signalling, which may be mediated via secretion of 
anti-inflammatory mediators. These findings hint at the intriguing possibility 
that some of the CD69+ peritoneal T-cells may perform a regulatory function, 
dampening down local immune responses [89, 94-96].
To further examine the reactivity pattern of the peritoneal T-cells, we 
investigated their TH1/TH2 cytokine profile. According to the TH1vs.TH2 
paradigm, effector T-cells are defined according to their cytokine profiles. TH1 
cells produce IFN-y and drive cell-mediated immune responses whereas TH2 
cells produce IL-4 and are associated with B-cell help and humoral responses 
[56, 58, 59]. Whilst previous studies have suggested that IFN-y levels are 
elevated during acute peritonitis, a detailed analysis of the TH1/TH2 axis in 
resident peritoneal T-cells has been lacking [54, 55, 97].
From our experiments we can conclude that in vitro stimulated peritoneal T- 
cells mount a pre-dominantly TH1-skewed immune response. TH1 responses 
also appear to dominate the in vivo situation as evidenced by the increased 
levels of IFN-y (but very little IL-4) detected in PD effluent during both 
peritonitis and the steady state.
The peritoneal TH1 bias is probably due to a combination of preferential 
recruitment of TH1 cells and DC driven polarisation of local undifferentiated 
cells. Many murine studies have shown that TH1 and TH2 cells display 
distinct migration patterns, with TH1 cells entering inflamed peripheral tissues, 
whereas TH2 cells enter lymph node and spleen (the inflamed asthmatic lung 
is an exception here as it contains an abundance of TH2 cells) [98]. Evidence 
for the role of DC in peritoneal T-cell polarisation comes from in vitro work 
showing that DC skew stimulated PBMC towards a TH1 reactivity profile [26]. 
Further evidence comes from the observation that IL-12 levels are greatly 
increased during the early stages of peritonitis. The formation of a TH1 
response is highly dependant on IL-12, suggesting that this DC derived
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cytokine is skewing the local peritoneal immune response towards a TH1 bias 
[97, 99].
The TH1 response is pivotal for both bacterial clearance and immuno- 
resolution. In terms of pathogen clearance, IFN-y serves to activate 
peritoneal macrophages and promote bactericidal activity. In terms of 
resolution, IFN-y (in combination with IL-6 ) has been shown to abrogate 
neutrophil recruitment and promote neutrophil apoptosis thus limiting host 
damage [46, 52]. It should be noted that we did not attempt to deliberately 
skew the peritoneal T-cells to a TH2 phenotype in these experiments ( e.g. by 
culturing in an IL-4 rich environment). Consequently it remains feasible that 
under appropriate conditions (e.g. within omental milky spots or peritoneal 
lymph nodes) peritoneal T-cells may adopt a TH2 phenotype allowing them to 
stimulate/support local B-cells
In addition to cytokine production, immuno-competent T-cells must retain 
proliferative capacity so that they can generate a secondary wave of antigen 
specific effector cells. Some authors have suggested that resident peritoneal 
T-cells exist in a state of anergy and do not proliferate in response to 
stimulation [100]. Our initial work seemed to confirm this, since unlike 
matched peripheral blood T-cells, purified peritoneal T-cell did not appear to 
proliferate in response to OKT3. We subsequently refined these experiments 
and were able to demonstrate that peritoneal T-cells can in fact proliferate 
when cultured in the presence of allogenic peritoneal APC.
Why is peritoneal T-cell proliferation so highly dependent on APC? A more 
refined analysis of the peritoneal T-cell: APC interaction suggests that this 
accessory cell requirement is mainly dependent on direct cell-cell contact. 
One possible explanation for this relates to the fact that OKT3 is a monoclonal 
antibody. The APC contain receptors capable of binding the Fc portion of the 
antibody, thus creating a matrix of cross-linked TCRs and activating the T- 
cells (Figure 3.11).
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Figure 3.11 TCR cross linking -  a possible explanation for APC dependence.
APC bind the Fc portion of the OKT3 molecule. Subsequent clustering of the TCR 
results in T-cell activation
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If this explanation were correct then plate bound OKT3 should mimic this 
effect by cross-linking TCR. The poor proliferation observed with plate bound 
OKT3 and plate bound CD3 suggests that APC are not acting solely via 
engagement of Fc binding. We speculate that other factors such as contact 
with APC derived co-stimulatory molecules are necessary to drive peritoneal 
T-cell proliferation. These co-stimulatory molecules have been well described 
elsewhere and include CD80 (B7-1) and CD8 6  (B7-2) [97, 101].
The trans-well data also highlight an important role for APC-derived soluble 
factors in promoting T-cell proliferation. We speculated that IL- 6  may have 
been one of these factors (given its well documented role in the peritoneal 
immune response). Our results were inconclusive (possibly reflecting the 
small number of patients analysed) so that we were unable to draw any firm 
conclusions regarding the role of II-6  in peritoneal T-cell proliferation.
Having established that proliferation of peritoneal T-cells isolated during the 
steady (non-infected) state are dependant on APC co-stimulation, we next 
extended our study to examine the proliferation of peritoneal T-cells isolated 
during acute peritonitis. These T-cells are a short lived population, recruited 
in large numbers from the blood on days 4-6 of infection [C Parker, 
unpublished data] then rapidly cleared from the peritoneum. We discovered 
that (similar to peripheral blood T-cells) these cells were not dependant on 
APC for in-vitro proliferation and in fact the peritoneal APC appeared to have 
a suppressive effect on the proliferation of these cells, promoting activation 
induced cell death (AICD).
These findings hint at a dual role for peritoneal APC in regulating T-cell 
proliferation. During the steady state, slow turnover of resident peritoneal T- 
cells is likely to occur only in peritoneal lymph nodes where T-cells come into 
contact with peritoneal DC. This dependency on DC co-stimulation minimises 
non-specific T-cell proliferation in response to innocuous peritoneal or 
environmental antigens. During acute peritonitis vast numbers of effector T- 
cells are recruited from the blood into the peritoneal cavity. Following 
pathogen clearance, it is imperative that the majority of these (now redundant)
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effector cells are removed, DC appear to expedite this process by promoting 
apoptosis in this population.
3.4 Conclusion
In conclusion, we have identified significant differences between peripheral 
blood and peritoneal T-cells with regards to their activation status and 
proliferative capacity. Peritoneal T-cells express increased levels of CD69, 
(which may serve a regulatory function) and respond to stimulation with a TH1 
mediated response. They appear to have a higher activation threshold than 
peripheral blood cells and their proliferation is tightly regulated by peritoneal 
DC. This suggests that intricate control mechanisms are in place to 
streamline the peritoneal immune response, contributing to replete host 
defence without causing host damage.
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Chapter 4
Characterisation of Specialised Peritoneal T-ceil
Sub-Populations
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4.1 Introduction
Amongst the most exciting recent developments in the field of immunology 
has been the identification of specialised effector subsets within the T-cell 
repertoire. These include memory subsets, regulatory T-cells, IL-17 
producing T-cells and Vy982 cells. Their characterisation has provided new 
insights into the complexity of the human innate and adaptive immune 
responses and how T-cells contribute to immune-surveillance [59, 61, 62, 6 6 , 
67, 75-79].
The current definition of memory T cells recognises central memory cells 
(Tcm), effector memory cells (TEm) and terminally differentiated effector 
memory cells (TEMRA). These memory subsets differ in both phenotype and 
function. Tcm (CD45R0/CCR7+/CD62LHi) express lymph node homing 
receptors and localize to lymphatic tissue where they are thought to respond 
to TCR stimulation by proliferation. Tem (CD45R0/CCR77CD62I_Lo) lack these 
lymph homing receptors and localize to peripheral tissues, providing an 
immediate response to infection [59, 79, 80]. These subsets have not, as yet 
been characterised in the peritoneal cavity.
Regulatory T-cells (T-regs) are well known to maintain peripheral tolerance 
and prevent autoimmunity. A growing body of evidence also suggests that T- 
regs are pivotal in regulating the host’s response to infection [68-71]. Closely 
related to T-regs are the IL-17 producing CD4+T cells (TH17 cells). There is 
emerging evidence that these cells are instrumental in the pathogenesis of 
numerous human diseases including psoriasis, colitis and multiple sclerosis 
(MS) [61]. Their role in the host response to bacterial infection is less well 
defined.
Another recently identified T-cell subset that have attracted much attention 
are the Vy982 T-cells. Whilst most peripheral blood T-cells express the 
TCRap on their surface, a minority (2-20%) express the TCRy8 . The most 
abundant y8  T-cells are the subset expressing the Vy982 TCR. These cells
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are unique in that they recognise low molecular weight non-peptide 
compounds in an MHC independent manner. The most potent stimulant of 
Vy9S2 T-cells is E-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), a 
metabolite produced by many infective agents including most species of 
Gram-negative bacteria. There is growing evidence that these cells may 
govern the early phase of the innate immune response to bacterial infection, 
although no data exists on their role in the peritoneal cavity [75-78].
The interest generated by these findings is reflected in the developing 
literature describing the phenotype and function of these T-cell sub­
populations. It should however be noted that the vast majority of these 
studies describe T-cells obtained from murine models of inflammation and 
disease. Concerns have thus been raised that the findings of such studies 
may have limited applicability to human disease. Since the mice are kept in 
germ-free or essentially pathogen-free facilities it is well recognised that they 
have much lower levels of endogenous T-cell activation than the human 
system [70]. Clearly the simple answer is to perform all research on human 
samples, however this is not always feasible since access to human 
(especially peripheral tissue) cells is hampered by the need for invasive 
access. The unique nature of PD therapy has given us a rare opportunity to 
analyse specialised T-cell subsets within the context of human peripheral 
tissue inflammation.
The specific aims of this chapter are:
a) Characterise the memory phenotype of the peritoneal T-cell population.
b) Identify and characterise peritoneal T-cell sub-populations (T-regs / 
TH17 cells and Vy962 T-cells).
c) Examine the role of Vy952 T-cells in the peritoneal immune response to 
infection.
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4.2 Results
4.2.1 Peritoneal T-cell memory subsets
To determine the “memory phenotype” of peritoneal T-cells, we analysed the 
surface expression of CD45R0 and CCR7 in paired samples of cells isolated 
from peripheral blood and PD effluent (Figure 4.1). When compared to 
peripheral blood, the peritoneum is depleted of naive cells and enriched in 
Tem cells (Figure 4.2). We further extended our phenotypic analysis to include 
the expression of the lymph node homing signal CD62L. We observed that 
CD62L expression is lower on peritoneal T-cells than peripheral blood T-cells. 
We also found that within the memory subsets, CD62L expression decreases 
progressively from naive through Tcm to Tem (Figure 4.3) [59, 80].
4.2.2 CD127 expression pattern of memory subsets
In an attempt to distinguish long-lived effector memory cells from recently 
activated effector cells (both of which express CD45R0) we examined CD127 
expression on peritoneal T-cells. IL-7 signalling via CD127 (the IL-7R) is 
thought to confer anti-apoptotic properties to T-cells. We observed that (as 
compared to naive cells) a sub-group of peritoneal memory cells express very 
high levels of CD127 (Figure 4.4).
4.2.3 Peritoneal T-cells mount a TH1 response to standard recall 
antigens
Murine data suggests that immediate effector cytokine production is a function 
of the Tem subset. To determine whether this was also true of peritoneal T- 
cells we stimulated them with PMA(500ng/ml) and lonomycin (50ng/ml) then 
analysed IFN-y production. As predicted, the predominant early TH1 
response to stimulation came from the Tem subset (Figure 4.5).
Next, we used an ELISpot assay to investigate the antigen specificity of this 
response. Paired samples of peripheral blood and peritoneal T-cells were 
exposed to the standardized recall antigens PPD (purified protein derivative of 
Mycobacterium tuberculosis), HA (Haemagglutinin antigen derived from
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Figure 4.1 A comparison of peritoneal and peripheral blood T-cell memory subsets
Paired samples of PBMC and peritoneal leukocytes were collected from PD patients. Cells 
were labeled with fluorescently conjugated monoclonal antibody directed against 
CD4/CD8/CCR7 and CD45R0. A combined gate was set on peritoneal T-cells based on 
CD4 or CD8 expression and their FSC:SSC profiles. Results show representative example 
from 20 patients (see appendix for patient demographics).
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Figure 4.2 A comparison of peritoneal and peripheral blood T-cell memory subsets
Paired samples of PBMC and peritoneal leukocytes were collected from PD patients. Cells 
were labeled with fluorescently conjugated monoclonal antibody directed against 
CD4/CD8/CCR7 and CD45R0. A combined gate was set on peritoneal T-cells based on 
CD4 or CD8 expression and their FSC:SSC profiles. Summary of data obtained from 
paired blood and peritoneal T-cells obtained from 20 patients. Differences between groups 
were tested using the Wilcoxan signed ranks test (see appendix for patient demographics).
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Figure 4.3 CD62L expression on (A) peripheral blood and (B) peritoneal T-cell 
memory subsets. Paired samples of PBMC and peritoneal leukocytes were collected from 
PD patients. Cells were labeled with fluorescently conjugated monoclonal antibody directed 
against CD4/CD62L/CCR7 and CD45R0. A combined gate was set on T-cells based on 
their CD4 expression and their FSC:SSC profiles, further gates were plotted on the CD4 
memory subsets (naive/central memory/effector memory) as shown above (see appendix 
for patient demographics).
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Figure 4.4 IL-7R expression on T-cell memory subsets. Peritoneal leukocytes were 
obtained from overnight PD effluent. Cells were labeled with fluorescently conjugated 
monoclonal antibody directed against CD4/CD45R0/CCR7 and IL-7R (CD127). A 
combined gate was set on peritoneal T-cells based on CD4 expression and their FSC:SSC 
profiles, further gates were plotted on the CD4 memory subsets (naive/central 
memory/effector memory) as shown above. Results display the percentage of cells within 
these memory subsets which are iL-7Rdim/IL-7Rlntermediate(|NT) or IL-7R Br'9ht. Representative 
example of 3 separate donors shown (see appendix for patient demographics).
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Figure 4.5 Peritoneal memory subset TH1 response. Peritoneal leukocytes (2x105/well) 
were stimulated with PMA (500ng/ml)/lonomycin (50ng/ml) for 2 hours. Cells were labeled 
with fluorescently conjugated monoclonal antibody directed against CD4/CD45R0/CCR7. 
Cells were subsequently fixed and permeabilized then stained with anti-IFN-y. A combined 
gate was set on peritoneal T-cells based on CD4 expression and their FSC:SSC profiles, 
further gates were plotted on the CD4 memory subsets (naive/central memory/effector 
memory). Results show the percentage of IFN-y+ cells within these memory subsets. 
Results are a representative example of experiments performed on 4 separate donors (see 
appendix for patient demographics).
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Influenza virus) and TT (Tetanus toxoid). Our results demonstrate that 
peritoneal T-cells are able to mount a TH1 response to these recall antigens, 
moreover these responses are increased in peritoneal T-cells when compared 
to peripheral blood T-cells, confirming that the “phenotypic” memory cells also 
exhibit long term recall function (Figure 4.6).
4.2.4 TCRVp expression patterns
Although we can test recall responses to a few pathogenic species (e.g. TB 
and Influenza) we lack standard in-vitro recall antigens for most of the species 
that cause peritonitis (e.g. Staphylococcus spp). In view of this we decided to 
use an alternative approach, analysing the TCRVp repertoire of peritoneal T- 
cells to identify whether peritoneal infection resulted in the formation of 
specific populations of memory T-cells. The TCR of apT-cells is a heterodimer 
composed of an a and p chain. The TCR gene locus contains Constant(C), 
Variable(V), Diversity(D) and Joining(J) segments each of which exist in 
multiple copies. The generation of TCR diversity occurs by combinational 
joining of these gene segments. Antigenic stimulation of T-cells leads to 
oligoclonal expansion of cells expressing common VDJ segments, whereas 
superantigen stimulation leads to polyclonal expansion of cells expressing a 
particular TCRVp family [102, 103]. We speculated that if peritonitis resulted 
in clonal expansion of peritoneal memory cells, these cells would be 
detectable as a local clonally expanded population, all sharing the same 
TCRVp repertoire.
TCRVp expression was examined by flow cytometry in paired samples of 
peripheral blood and peritoneal T-cells. The blood/peritoneal TCR repertoire 
was similar in patients with no previous peritonitis or previous Staphylococcus 
epidermidis peritonitis. In contrast, patients who had a previous history of 
Staphylococcus aureus peritonitis displayed polyclonal expansion of 
peritoneal T-cells (Figure 4.7).
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Figure 4.6 Peritoneal T-cell recall responses. Paired samples of PBMC and peritoneal 
leukocytes were collected from PD patients. ELISpot plates were coated with 50 pL anti- 
IFN-y antibody in sterile PBS (10pg/ml) and incubated at 4*C for 180mins. Peritoneal 
leukocytes and PBMC were plated out at 2x105 cells per well. Cells were incubated at 
37*C for 16h in the presence of purified protein derivative (PPD) (10 pg/ml), Tetanus 
Toxoid (TT) (5 pg/ml) or Haemaglutinin (HA) (5pg/ml). The ELISpot assay was developed 
according to the manufacturer’s instructions. (A) Representative example of 
Haemaglutinin recall response in peripheral blood and peritoneal T-cells. (B) Summary of 
recall response data from an individual patient. Results show mean ±SE of triplicate 
observations. Representative example of 4 donors is shown (see appendix for patient 
demographics).
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Figure 4.7 TCRVp repertoire of peripheral blood and peritoneal T-cells. Paired 
samples of PBMC and peritoneal leukocytes were collected from PD patients. Cells were 
labeled with fluorescently conjugated monoclonal antibody directed against CD3 and the 
various TCRVp families. A combined gate was set on peritoneal T-cells based on CD3 
expression and their FSC:SSC profiles. (A) Representative TCRVp repertoire from never 
infected patients (n=5). (B) Representative TCRVp repertoire from a patient with previous 
Staphylococcus epidermidis peritonitis (n=10). (C) Representative TCRVp repertoire from 
a patient with previous Staphylococcus aureus peritonitis (n=3). Results show the 
percentage of CD3+ T-cells expressing the TCRVp family (see appendix for patient 
demographics).
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4.2.5 Characterisation of peritoneal regulatory T-cells (T-regs)
To determine whether the peritoneal cavity of stable PD patients contains a 
population of T-regs, we analysed the peritoneal effluent for the presence of 
CD3+/CD4+/CD25+/Foxp3+ T-cells. As shown by the representative scatter 
plots (Figure 4.8A) the peritoneal cavity contains a distinct population of cells 
bearing this characteristic T-reg-like surface phenotype.
We subsequently compared the frequency of T-regs in paired samples of 
peripheral blood and peritoneal leukocytes isolated from a group of stable (i.e. 
infection free for at least 3 months prior to collection) PD patients. The 
frequency of T-regs within the peritoneal leukocyte pool was significantly 
higher (p=0.01) than the frequency of T-regs in the peripheral blood of the 
same individuals, suggesting that the peritoneal cavity is enriched in T-regs 
(Figure.4.8B).
4.2.6 Peritoneal T-regs are functional and retain their suppressive 
function
Although generally accepted that Foxp3 expression distinguishes T-regs from 
effector T-cells, there remains some controversy regarding the exact T-reg 
phenotype with some authors reporting transient up-regulation of Foxp3 
expression in effector (non-suppressive) T-cells [6 6 ]. In view of this we felt it 
was necessary to demonstrate that peritoneal T-regs did indeed have 
suppressive function. To investigate this further, peritoneal T-regs were 
isolated by FACS (see Materials and Methods section 2.9.2) and added to 
stimulated autologous responder T-cells. Although the sorted cell populations 
were not irradiated (and thus may themselves proliferate), our results 
demonstrate that peritoneal T-regs display potent suppressive function. 
(Figure 4.9).
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Figure 4.8 Identification of Peritoneal T-regs (A) Paired samples of peripheral blood 
and peritoneal T-cells were isolated from PD patients. T-cells were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3/CD4 and CD25. Cells 
were subsequently fixed and permeabilized then stained with anti-Foxp3. A gate was set 
on peritoneal T-cells based on their FSC/SSC profile and CD3/CD4 expression pattern. 
CD25 and Foxp3 expression was examined within this gated population. (A) 
Representative example of peripheral blood and peritoneal T-regs (results display 
percentage of CD4+/CD25+/Foxp3+ T-regs within the CD3+ T-cell pool). (B) Summary of 
data from paired blood and peritoneal T-cells obtained from 12 patients (horizontal lines 
represent the mean). Differences between groups were tested using the Wilcoxan signed 
ranks test.
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Figure 4.9 Peritoneal T-reg suppressive function. Paired samples of PBMC and 
peritoneal leukocytes were isolated from PD patients. Peritoneal leukocytes were 
labeled with fluorescently conjugated monoclonal antibody directed against CD3/CD4 
and CD25. Pure populations (>98%) of CD4+/CD25Hi (T-regs) and CD4+/CD25Lo (control) 
peritoneal T-cells were isolated by flow cytometry and cell sorting (FACS). (A)The sorted 
cells were added to OKT3 stimulated allogenic peripheral blood T-cells (responder 
population) at a T-cell:T-reg ratio of 5:1. T-cell proliferation (3H-Thymidine incorporation) 
was assessed at 96h. Proliferation results shown as mean of duplicate culture wells 
(horizontal lines represent mean of 5 patients) (B) The sorted peritoneal cells were added 
to allogenic PBMC cultures (PBMC:T-cell ratio 5:1). Cells were subsequently stimulated 
with PMA (500ng/ml)/lonomycin (50ng/ml). Following 4h of stimulation, PBMC were 
labeled with fluorescently conjugated monoclonal antibody directed against CD3. Cells 
were fixed, permeabilized then stained with anti-IFN-y. A combined gate was set on T- 
cells based on CD3 expression and their FSC:SSC profiles. Results show the 
percentage of IFN-y+ T-cells (horizontal lines represent mean).
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4.2.7 Mechanism of T-reg suppression
To determine whether peritoneal T-reg suppression was dependent on cell- 
contact, purified peritoneal T-regs (from stable PD patients) were co-cultured 
with stimulated autologous peripheral blood T-cells in a trans-well culture 
system (Figure 4.10A). In these experiments direct cell-cell contact was 
required for maximal T-reg suppression. When the T-reg and responder 
PBMC were separated by the insert, cell proliferation was still observed albeit 
at a lower level suggesting that T-reg derived soluble factors appear also 
have significant suppressive function (Figure 4.1 OB). Since both IL-10 and 
TGFp have both been previously identified as potent T-reg derived anti­
proliferative and anti-inflammatory cytokines [104], we used blocking 
antibodies directed against both IL-10 and TGFp in these trans-well 
experiments. As shown in Figure 4.10C blocking IL-10 and TGFp only 
partially abrogated T-reg suppressive function.
4.2.8 Peritoneal IL-17 producing T-cells (TH17)
To identify whether TH17 cells are present or can be derived from T-cells in 
the dialysed peritoneal cavity, isolated peritoneal T-cells were collected from 
both stable patients and from patients suffering bacterial peritonitis. Cells 
were stimulated in-vitro with PMA (500ng/ml) and lonomycin (50ng/ml) and IL- 
17 expression was analysed by flow cytometry. We only detected TH17 cells 
in 2 of the 15 patients analysed (Figure 4.11 A). One of these patients had 
severe, non-resolving Staphylococcus epidermidis peritonitis, while the other 
had Gram-negative peritonitis (It should also be noted that in these 2 patients 
TH17 cells were only detectable after further in-vitro stimulation i.e. not 
immediately ex-vivo).
In a separate series of patients, analysis of PD effluent by LUMINEX multiplex 
ELISA showed detectable levels of IL-17 early (days 1 and 2) in the course of 
peritonitis, suggesting that small populations of peritoneal IL-17 producing 
cells (although not always detected by FACS analysis) are present during 
infection (Figure 4.11B).
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Figure 4.10 Mechanism of peritoneal T-reg suppression. Paired samples of PBMC 
and peritoneal leukocytes were isolated from PD patients. Peripheral blood T-cells were 
isolated by magnetic column negative selection. Peritoneal leukocytes were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3/CD4 and CD25. Pure 
populations (>98% purity) of CD4+/CD25Hi peritoneal T-regs were isolated by flow 
cytometry and cell sorting (FACS). (A) Trans-well inserts were used to prevent direct cell­
cell contact. (B) Peripheral blood T-cells were stimulated with OKT3(10ng/ml) and IL-2 
(25U/ml), either in direct contact with peritoneal T-regs (T-cell:T-reg ratio, 5:1) or with 
peritoneal T-regs on the opposite side of a trans-well insert membrane. Proliferation(3H- 
Thymidine incorporation) was assessed at 96h. Results show mean of duplicate cultures 
(horizontal lines represent mean of 3 patients). (C) Peritoneal T-regs(CD3+/CD4+/CD25Hi) 
isolated by FACS were added to cultures of allogenic peripheral blood T-cells (T-cell:T- 
reg ratio 5:1). Cells were stimulated with OKT3(10ng/ml) and IL-2(25U/ml), in the 
presence or absence of anti-IL-10/anti-TGFp(both 10pg/ml). Proliferation(3H Thymidine 
incorporation) was assessed at 96h. Results show mean of duplicate cultures (horizontal 
lines represent mean of 3 separate patients; see appendix for patient demographics)
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Figure 4.11 Identification of peritoneal TH17 cells. (A) Peritoneal leukocytes were 
collected during Gram -ve peritonitis (day 5). Cells were stimulated with PMA (500ng/ml)/ 
lonomycin (50ng/ml) for 4 hours in the presence of monensin (2pM). Cells were labeled 
with fluorescently conjugated monoclonal antibody directed against CD3. Cells were 
subsequently fixed and permeabilized then stained with anti-IL17. A gate was set on 
peritoneal lymphocytes based on their FSC:SSC profiles, the percentage of IL-17+ cells 
(within the CD3+ population) was calculated. (B) Serial samples of peritoneal effluent was 
collected from patients suffering from acute peritonitis. IL-17 levels were analysed with a 
multiplex bead-based cytokine assay. Results show mean ±SE of n=12 separate patients 
(see appendix for patient demographics).
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4.2.9 Peritoneal Vy982 T-cells
We next examined whether the peritoneal cavity contains a population of 
Vy952 cells as part of its innate immune defence armoury. As demonstrated 
in Figure 4.12, a population of Vy9S2 cells was detected by FACS analysis. 
These peritoneal Vy962 cells expressed an inflammatory phenotype as 
characterised by increased expression of CCR5 and decreased expression of 
CCR7 (Figure 4.12D). Stimulation of these cells with the Vy962 cells agonist 
HMB-PP resulted in selective activation (CD25 up-regulation) and TH1 
cytokine production (Figure 4.12B and C). Furthermore, in a single 
experiment, exposure of PBMC to cell free peritoneal effluent freshly collected 
from a patient suffering Gram-negative peritonitis resulted in selective 
activation of Vy962 cells. These observations suggest that this effluent may 
contain HMB-PP or an equivalent activating principal (Figure 4.13). It should 
be noted that repeating this experiment with stored samples of Gram-negative 
PD effluent failed to activate Vy952 cells. This may reflect the documented 
instability of HMB-PP in biological fluids.
4.2.10 Vy962 Cell recruitment profile
Previous reports suggest that Vy962 cells regulate the early phase of the 
inflammation [75]. To determine their role in the peritoneal immune response, 
we utilised flow cytometry to follow their recruitment profile. Although limited, 
these data suggest that Vy962 cells appeared to be selectively recruited from 
the blood during the first few days of Gram-negative (but not Gram-positive) 
infection (Figure 4.14).
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Figure 4.12 Characterisation of peritoneal Vy982 cells. (A) Paired samples of PBMC 
and peritoneal leukocytes were isolated from PD patients. Leukocytes were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3 and Vy9. Results 
shown as percentage of CD3+ cells (representative example shown of 5 separate donors; 
see appendix for patient demographics.) (B) Peritoneal leukocytes were stimulated with 
HMB-PP(100pmol/ml) for 12 hours. Cells were labeled with fluorescently conjugated 
monoclonal antibody directed against CD3A/y9/CD25. To determine the percentage of 
activated cells, a gate was set on either the ap or y8 subset and the percentage of positively 
staining cells within this gate was calculated (representative example shown of 3 separate 
donors; see appendix for patient demographics). (C) Peritoneal leukocytes were stimulated 
for 12 hrs with HMB-PP(100pmol/ml). Cells were labeled with fluorescently conjugated 
monoclonal antibody directed against CD3/ Vy9. Cells were subsequently fixed and 
permeabilized then stained with anti-IFN-y. To determine the percentage of activated cells, 
a gate was set on either the ap or y6 subset and the percentage of positively staining cells 
within this gate was calculated (representative example shown of 3 separate donors; see 
appendix for patient demographics). (D) Peritoneal leukocytes were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3A/y9/CCR5 and CCR7. 
Results shown as percentage of Vy9S2 cells expressing CCR5 or CCR7 (mean and SE of 8 
separate patients; see appendix for patient demographics).
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Figure 4.14 Temporal profile of Vy982 cell recruitment during peritonitis. Peritoneal 
leukocytes were collected during episodes of peritonitis. Cells were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3/Vy9 (see appendix for 
patient demographics).
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4.3 Discussion
The past few years have witnessed numerous groundbreaking developments 
in the world of T-cell research. This has resulted in a paradigm shift so we 
now recognise that many unique T-cell subsets, each with distinct functional 
characteristics contribute to the regulation of both acquired and even innate 
immunity. To date however, the majority of this knowledge has been gleaned 
from murine studies, so that we know much less about the phenotype and 
function of these sub-populations in human peripheral tissue T-cells. The 
unique nature of PD therapy provides us with an opportunity to analyse the 
phenotype and function of these specialised subsets in the human system.
We began our analysis by looking for the presence of memory T-cells within 
the peritoneal cavity. The ability to generate long-lived antigen specific 
memory is the hallmark of the adaptive immune system. Upon re-exposure to 
the primary antigen, memory cells mount an immediate recall response, thus 
enhancing pathogen clearance. Though previous authors have suggested 
that peritoneal T-cells express CD45R0 (a marker of memory), these studies 
pre-date the current model of T-cell memory which recognises naive/central 
memory (Tcm) / effector memory (Tem) or TEMRA (terminally differentiated 
effector cells) subsets [59, 80].
We have shown that, when compared with blood the peritoneal cavity is 
enriched in Tem (CD45R0+/CCR77CD62I_Lo) cells and depleted of naive T- 
cells (CD45R07CCR7+/CD62LHi). The peritoneal recruitment of Tem is likely 
facilitated by their increased expression of pro-inflammatory chemokine 
receptors such as CCR5 whose ligands (Mip, RANTES) are expressed within 
the peritoneum [50, 75, 77].
We performed further phenotypic analysis of these cells looking for 
expression of survival signals. Long-term survival is a hallmark of memory 
cells; it is the defining feature that distinguishes them from short-lived effector 
cells. This survival is antigen independent and relies on signals provided by
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cytokines, in particular IL-7 and IL-15. Whereas IL-15 maintains homeostatic 
proliferation, IL-7 is thought to act as a survival signal, up-regulating 
expression of anti-apoptotic molecules [105]. Our phenotypic analysis of the 
peritoneal T-cells identified that CD127 (the IL-7 receptor) expression was 
higher on peritoneal T-cells; in particular a subset of CD45R0 cells expressed 
very high levels of CD127. It is likely therefore that the CD45R0+/CCR7' 
/CD62LLo/CD127Hi cells are the true long-lived memory cells, whereas the 
CD45R0+/CCR7'/CD62LLo/CD127dim group may represent short-lived effector 
cells. [76]. In this context it is interesting to note that previous studies have 
documented that stimulated HPMC produce IL-15, which suggests that the 
peritoneum may form a selective niche rich in survival signals that promote 
memory T-cell longevity [23]. The finite availability of such survival signals 
within the peritoneum may serve to restrict the expansion of memory cells, 
thus maintaining homeostasis [97,106].
Having established the baseline phenotype of the peritoneal memory subsets 
we next examined their functional characteristics. In agreement with current 
opinion, immediate/early TH1 cytokine production was a function of the Tem 
subset. Using a more refined, antigen specific stimulation, we were able to 
show that the peritoneal Tem mount a TH1 recall response to standard 
antigens (TB, Tetanus Toxoid and Infeuenza). Of note, when compared to 
blood the peritoneum was enriched in cells capable of mounting a recall 
response. This is interesting for two reasons. Firstly it confirms that the 
peritoneal “memory phenotype” cells do indeed display long-term antigen- 
specific memory. Secondly, it gives us new insight into the trafficking 
mechanisms of memory cells, suggesting that cells formed at the site of 
vaccination migrate selectively into peripheral tissues such as the peritoneum. 
This may have evolved as a defence mechanisms ensuring that an immediate 
response is available in the periphery.
Since we lacked an in-vitro recall antigen to the common causes of peritonitis, 
we adopted an alternative strategy to determine whether peritonitis leads to 
local expansion of memory cells. We analysed the TCRVp expression 
repertoire of peritoneal and peripheral blood T-cells isolated from PD patients.
102
Peritoneal T-cells from infection free or from patients with a previous history of 
Staphylococcus epidermidis peritonitis displayed similar TCRVp expression 
profiles to peripheral blood T-cells. In contrast, peritoneal T-cells isolated 
from patients with previous Staphylococcus aureus peritonitis displayed some 
skewing of TCRVp usage suggesting that this pathogen (which, unlike S. 
epidermidis produces superantigens) may promote the expansion of local 
long-lived memory clones. The absence of S. epidermidis specific memory 
cells, may explain in part why recurrent infection (with the same organism or 
the continuous presence of Coagulase negative Staphylococcal spp. in the 
bio-film lining the PD catheter) does not result in host immunity to that 
organism [102, 107]. Similarly the oligoclonal expansion of peritoneal T-cells 
triggered by S. aureus infection, may be responsible for the increased 
immune activation seen in peritonitis with this organism [54, 108].
From our analysis of peritoneal memory cell phenotype and function we can 
begin to predict their behaviour in the context of the peritoneal immune 
response. Since they lack the lymph node homing signals (CCR7 and 
CD62L), the peritoneal TEm subset is likely to remain within the peritoneal 
cavity where they contribute to defence mechanisms against invading 
organisms. They are, in effect primed cells, responding rapidly to infection by 
mounting a TH1 polarised cytokine response. In contrast, TCm express both 
CD62L and CCR7 and are likely to migrate to the peritoneal lymph tissue 
where they would be ideally placed to encounter antigen loaded DC (also 
CCR7+). In this way Tcm could “screen” vast numbers of APCs for their 
cognate antigen. Upon re-activation Tcm are likely to proliferate, thus 
generating a wave of antigen specific effectors.
Having focused on the effector memory cell population, we next investigated 
the regulatory/suppressive components of the peritoneal immune response. 
We have now identified for the first time a T-cell subset fulfilling the 
phenotypic definition of T-regs existing within the peritoneal cavity of PD 
patients. Moreover we have shown that when compared to the peripheral 
circulation, T-regs are enriched in the peritoneal cavity of PD patients. The T-
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reg enrichment may either represent expansion of a local population or 
selective recruitment of T-regs from the circulation.
We were able to demonstrate that peritoneal T-regs display potent 
suppressive activity and are capable of abrogating both the proliferation and 
TH1 (IFN-y production) effector function of autologus peripheral blood T-cells. 
The mechanisms that underpin T-reg mediated suppression are complex and 
poorly understood. Recent in vitro work has suggested that suppression is 
cell-contact dependant, mediated via disrupting the DC: effector T-cell 
interaction. This contrasts somewhat with in vivo observations, which suggest 
that T-reg suppression is mediated via production of anti-inflammatory 
mediators, most notably IL-10 and TGFp [74, 104]. Our own in vitro 
observations of peritoneal T-regs suggest that suppression is dependent on 
direct cell-cell contact with a limited role for IL-10 and TGFp .
When considering the behaviour of peritoneal T-regs in-vivo we must consider 
that within the peritoneal cavity there is ample space for effector cells to avoid 
direct cell-cell contact. In view of this, we speculate that cell-cell contact 
mechanisms occur predominantly within the draining lymph nodes (where DC, 
effectors and T-regs are in close proximity) whilst secretion of IL-10 and TGFp 
may maintain suppression within the cavity itself.
What role do these suppressive mechanisms play in the complex multi­
faceted peritoneal immune system? The nature of PD therapy means that 
this system is constantly exposed to foreign antigens and inflammatory 
stimuli. Under such circumstances peritoneal T-regs serve to maintain 
homeostasis by suppressing effector cell function. During acute peritonitis, 
this equilibrium shifts towards a pro-inflammatory phenotype, so that the 
invading pathogen can be cleared. T-regs are likely to play a pivotal role in 
regulating the magnitude of this inflammatory response, minimising host 
damage, promoting immuno-resolution and preventing chronic inflammation.
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Closely related to T-regs are the pro-inflammatory IL-17 producing subset 
(TH17). Interestingly, these two subsets with apparent divergent function are 
thought to derive from the same pre-cursor cell. During the steady state, the 
local cytokine milieu favours the formation of T-regs whereas during 
inflammation, the balance is shifted in favour of TH17 development [62]. 
Though numerous recent publications highlight the importance of TH17 in 
autoimmune disease, their anti-microbial role is poorly understood.
There is indirect evidence that TH17 cells may play a role in the peritoneal 
inflammatory response since HPMC express the IL-17 receptor and respond 
to IL-17 stimulation by producing C-X-C chemokines. Work from the same 
group has shown that intra-peritoneal injection of mice with IL-17 results in 
massive neutrophil accumulation [109-111]. We expanded on these 
observations by showing that elevated IL-17 can be detected in the PD 
effluent of patients suffering from peritonitis. We have also shown that TH17 
cells can be detected in the PD effluent of patients who have suffered 
prolonged or more severe episodes of inflammation. Collectively, these 
findings suggest that TH17 cells may be important during the early, ’’pro- 
inflammatory” phase of the peritoneal immune response, and that their 
expansion may reflect underlying dysregulated inflammation which may in 
turn lead to a worse outcome.
The final specialised sub-set that we investigated were the Vy9S2 T-cells. 
These T-cells differ fundamentally from ap T-cells with respect to the type of 
antigen recognised, mode of antigen recognition and chemokine receptor 
profile. Vy9S2 T-cell research is hampered by both the lack of appropriate 
animal models (Vy962 T-cells do not exist in rodents), and the lack of readily 
accessible human samples [75-78]. Analysis of PD effluent during both the 
steady state and during peritonitis has given us fresh insight into the activation 
and recruitment patterns of these cells.
Our data shows that Vy962 T-cells reside (in small numbers) within the non­
infected peritoneal cavity. These cells retain functional activity and can be
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selectively activated in vitro by HMB-PP. The number of intra-peritoneal 
Vy982 T-cells increased dramatically during the early phase (day 1-2) of 
Gram-negative peritonitis suggesting that they are selectively recruited into 
the inflamed peritoneum. This “early recruitment” of Vy952 T-cells precedes 
the bulk of ap T-cell recruitment which occurs at day 5-6, suggesting that 
Vy962 T-cells (along with neutrophils and monocytes) may form part of the 
early immune response. Their recruitment is likely to be facilitated by the “pro- 
inflammatory” phenotype (CCR5+/CCR7) which was displayed by the majority 
of circulating Vy982 T-cells, a phenotype which is shared by other “innate” 
system cells [75, 77].
Many of these cells display an “activated” phenotype, and though we did not 
measure HMB-PP levels directly, we have shown that Gram-negative effluent 
(but not Gram-positive effluent) selectively activates Vy982 T-cells. Though 
historically, Gram-positive organisms have been the most common pathogens 
associated with PD-related inflammation, the contribution of Gram-negative 
organisms such as Pseudomonas spp. has increased considerably over the 
past years. Gram-negative bacteria are well known to cause a clinically more 
severe infection, with higher rates of non-resolution, catheter removal, and 
even patient death [112, 113]. This hints to a correlation of morbidity and 
mortality with the potential of the causative agents to stimulate Vy982-T-cells. 
More recent data collected by our own group (analysing over 400 episodes of 
peritonitis) has confirmed this association (Figure 4.15).
Once recruited into the peritoneum, we speculate that Vy982 T-cells respond 
to microbial products (such as HMB-PP) in an MHC independent manner. 
They secrete further pro-inflammatory cytokines, amplifying the immune 
response before migrating to local lymph nodes as professional APCs. Within 
lymph nodes, Vy952 T-cells cells have the capacity to activate apT-cells thus 
initiating the adaptive immune response [77]. Clearly more work is needed to 
confirm this hypothesis, however it is becoming clear that Vy982 T-cells 
(similar to peritoneal DC) are likely to form a cardinal bridge between the 
innate and adaptive arms of the immune response [75].
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Figure 4.15 PD technique survival according to HMB-PP status of infecting 
organism. Data analysis based on first episode of peritonitis in 413 separate patients 
(Chess et al, unpublished data).
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4.4 Conclusion
We have shown for the first time that the peritoneal T-cell pool can be divided 
into specialised subsets displaying distinct and often divergent functions. An 
effective peritoneal defence requires that these cells work in unison to ensure 
timely pathogen removal with minimum host damage. Over-activity or 
deregulation of one of these subsets could compromise the immune response 
leading to either overwhelming infection or uncontrolled inflammation, both of 
which are likely to injure the host and limit the lifespan of the peritoneal 
membrane.
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Chapter 5
Peritoneal T-cell Phenotype and Function: 
the Impact of Recurrent Peritonitis
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5.1 Introduction
Recurrent peritonitis is the Achilles heel of PD therapy and remains the main 
cause of treatment failure [114]. Peritoneal biopsy data shows that there is a 
relationship between peritonitis and membrane fibrosis, with those individuals 
who have suffered recurrent peritonitis likely having the greatest degree of 
sub-mesothelial expansion [8 , 10]. This is further supported by autopsy 
studies demonstrating that peritonitis (but not duration of dialysis) is linked to 
membrane thickening [16].
We are now beginning to unravel the basic mechanisms that connect 
repeated infection with membrane fibrosis. It appears that recurrent infection 
and dialysis duration significantly alters the phenotype and function of the 
resident peritoneal cells, generating a chronic inflammatory milieu within the 
peritoneal cavity. Studies of human peritoneal macrophages have shown that 
recurrent infection appears to impair killing capacity and cytokine production 
[115]. This was believed by some authors to potentially contribute to a 
“burnout” phenomenon that rendered the peritoneal cavity compromised in 
terms of host defence. Studies by our own group have also show that 
recurrent episodes of peritonitis are associated with dysregulated HPMC 
signalling and neutrophil retention [C. Parker, unpublished]. Similar retention 
of inflammatory cells has been observed in the small intestine of patients 
suffering from Crohns disease and in the joints of patients suffering from 
Rheumatoid arthritis. Such aberrant leukocyte trafficking is the hallmark of 
chronic inflammation and is thought to be responsible for local tissue damage 
and fibrogenic processes [46, 47].
Since most host defence studies have concentrated on the peritoneal 
macrophage, we know very little about the impact of recurrent infection on the 
peritoneal T-cell. Data from the murine model of peritonitis suggests that 
infection leads to T-cell dysregulation, which in turn is a pivotal trigger for 
chronic inflammation [Topley, Jones unpublished data].
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The aims of this chapter are:
a) Characterise the impact of infection on resident peritoneal T-cell 
phenotype.
b) Characterise the impact of recurrent infection on resident peritoneal T- 
cell function.
c) Explore possible mechanisms that link recurrent infection with altered 
phenotype and function.
5.2 Results
5.2.1 Impact of recurrent infection on peritoneal T-cell effector 
function
To analyse the impact of infection on peritoneal T-cell proliferation, we first 
stratified patients according to their previous infection history (no episodes, 1 - 
2 episodes, >2 episodes). Peritoneal T-cells were isolated from these 
patients during infection-free periods (defined as a period of at least 3 months 
since their last episode of peritonitis) and stimulated ex vivo. As shown in 
Figure 5.1 multiple previous episodes of peritonitis are associated with 
significantly impaired ex vivo T-cell proliferation and IFN-y producing capacity. 
A stepwise multivariate analysis revealed that only the number of previous 
infections (and not time on PD) was significantly correlated with peritoneal T- 
cell effector function (p=0.028 for T-cell proliferation, p=0.001 for IFN-y).
We performed further experiments to determine whether the ex vivo T-cell 
changes observed in peritonitis patients are mirrored in vivo. To assess in 
vivo proliferation, peritoneal T-cells freshly isolated from the peritoneal cavity 
of infection free and previous peritonitis patients were stained immediately 
with antibody directed against the proliferating nuclear cell antigen Ki67. This 
nuclear protein is expressed by proliferating cells in all phases of the active
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Figure 5.1. Impact of recurrent peritonitis on peritoneal T-cell effector 
function. Peritoneal leukocytes were collected from stable (no infection in the past 
3months) patients. (A) Peritoneal T-cells (isolated by magnetic column negative 
selection) were stimulated with OKT3 in the presence of allogenic peritoneal APC. 
Proliferation (3H-Thymidine incorporation) was assessed at 96h. For data analysis 
patients were stratified into subsets according to their previous history of peritonitis 
(data presented as box and whisker plot for each subset). (B) Peritoneal leukocytes 
(2x105/well) were stimulated with PMA (500ng/ml)/lonomycin (50ng/ml) for 4 hours 
in the presence of monensin (2pM). Cells were labeled with fluorescently 
conjugated monoclonal antibody directed against CD3. Cells were subsequently 
fixed and permeabilized then stained with anti-IFN-y. A combined gate was set on 
peritoneal T-cells based on CD3 expression and their FSC:SSC profiles, the 
percentage of CD3+/IFN-y+ cells was calculated. For data analysis patients were 
stratified into subsets according to their previous history of peritonitis. The data for 
each subset is presented as box and whisker plots. Overall p values were 
calculated using the Kruksal-Wallis test (see appendix for patient demographics).
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cell cycle but is absent in resting cells and hence serves as a surrogate 
marker of cell proliferation [116]. In the limited number of experiments of this 
type that we performed there was a significantly lower Ki67 staining in 
peritoneal T-cells obtained from recurrently infected patients suggesting that 
the observed ex vivo proliferative defects are manifest in the in vivo setting 
(Figure 5.2A).
To assess cytokine production in-vivo, we also measured PD effluent cytokine 
levels in these same groups of patients. As shown in Figure 5.2B, IFN-y was 
present in the peritoneal cavity during steady state PD in patients without a 
history of infection, but was below the detection limit in patient samples from 
those with a history of peritonitis.
5.2.2 Impact of recurrent infection on TH1/TH2/TH17 axis
To determine whether recurrent infection caused a shift in polarisation from 
TH1 to TH2 orTH17, peritoneal T-cells from recurrently infected patients were 
stimulated with PMA (500ng/ml) and lonomycin (50ng/ml). As shown in 
Figure 5.3, the decreased TH1 response was not accompanied by an 
increased TH2/TH17 effector response.
5.2.3 Impact of recurrent infection on peripheral blood T-cell effector 
functions
During the collection of peritoneal effluent samples, we also obtained paired 
samples of peripheral blood T-cells from a subset of these patients. When 
compared to peritoneal T-cells, peripheral blood T-cells obtained from 
recurrently infected patients retained their effector function (as evidenced by 
no differences in IFN-y production between infected and never infected 
patients) (Figure 5.4).
5.2.4 Impact of recurrent infection on peritoneal T-cell phenotype
To analyze whether the observed alterations in T-cell function were due to 
changes in their global phenotype, we performed flow cytometric analysis on 
peritoneal T-cells obtained from the same patient cohort. We did not find any
113
A B
25 nCO
20 -
.2 ,0 15- <o =
(A Q>2> O
a  10-
(n=2)(n=2)
10 n
E
O)a
rz
LL
>3
(n=2)(n=2)
Number of peritonitis episodes Number of peritonitis episodes
Figure 5.2 In-vivo effector function of peritoneal T-cells. Peritoneal leukocytes were 
collected from stable (no infection in the past 3 months) patients. (A) Peritoneal 
leukocytes were stained with monoclonal antibody directed against CD3. Cells were 
subsequently fixed, permeabilised and stained with monoclonal antibody directed 
against Ki-67. Results show the percentage of CD3+ cells expressing ki67. (B) 
Peritoneal effluent was collected from patients during the steady (non-infected) state. 
IFN-y levels were analysed with a multiplex bead-based cytokine assay. For data 
analysis patients were stratified into subsets according to their previous history of 
peritonitis (mean ±SE for each subset shown; see appendix for patient demographics).
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Figure 5.3 TH1/TH2/TH17 axis of peritoneal T-cells isolated from recurrently infected 
patients. Peritoneal leukocytes were isolated from a subset (n=4) of the recurrent peritonitis 
cohort. Peritoneal leukocytes (2x105/well) were stimulated with PMA (500ng/ml)/lonomycin 
(50ng/ml) for 4 hours in the presence of monensin (2pM). Cells were labeled with 
fluorescently conjugated monoclonal antibody directed against CD3. Cells were 
subsequently fixed and permeabilized then stained with anti-IFN-y/anti-IL-4/anti-IL-17. A 
combined gate was set on peritoneal T-cells based on CD3 expression and their FSC:SSC 
profiles, the percentage of cytokine producing T-cells was calculated (horizontal lines 
represent the mean; see appendix for patient demographics).
Number of peritonitis episodes
Figure 5.4 Impact of recurrent peritonitis on peripheral blood T-cell effector 
function. Peripheral blood was collected from a subset of patients (n=8) and 
PBMC were isolated by Ficoll density gradient centrifugation. PBMC (2x105/well) 
were stimulated with PMA (500ng/ml)/lonomycin (50ng/ml) for 4h in the presence 
of monensin (2pM). Cells were labelled with fluorescently conjugated monoclonal 
antibody directed against CD3. Cells were subsequently fixed and permeabilized 
then stained with anti-IFN-y. A combined gate was set on T-cells based on CD3 
expression and their FSC:SSC profiles. The percentage of IFN-y+ cells was 
calculated. For data analysis patients were stratified into subsets according to their 
previous history of peritonitis. The data for each subset is presented as box and 
whisker plots.
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significant difference in the proportion of T Em nor TCm in these patients (Figure 
5.5). We did however find a trend towards increased T-regs within the 
peritoneal cavity of patients who had suffered recurrent peritonitis, though this 
did not reach statistical significance (Figure 5.6).
5.2.5 T-cell telomere length
To determine whether the observed changes in peritoneal T-cell function are 
related to cellular senescence, highly purified paired populations of peripheral 
blood and peritoneal CD3+ T-cells were obtained by FACS. T-cell telomere 
length was assessed by Single Telomere Length Analysis (STELA) [8 8 ]. 
Peritoneal T-cell telomeres were considerably shorter than matched 
peripheral blood T-cells, moreover PD patients had shortened peripheral 
blood T-cell telomeres as compared to healthy age-matched controls. 
Recurrent peritonitis did not have a significant effect on peritoneal T-cell 
telomere length (Figure 5.7).
5.3 Discussion
Recurrent peritonitis is known to have a significant detrimental impact on 
technique and patient survival [9, 112, 113]. To date the impact of infection 
on the human peritoneal immune system is poorly described. Though some 
evidence suggests that macrophage function is altered [2 1 ], the effect on 
peritoneal T-cell function has been largely ignored. There is emerging 
evidence from the mouse model of peritonitis to suggest that peritonitis has a 
significant effect on T-cell function, with T-cells adopting a primed “active” 
phenotype following repeated episodes of inflammation [Topley, Jones 
unpublished data]. In view of these findings, we assessed the impact of 
recurrent peritonitis on human peritoneal T-cell phenotype and function.
Our results suggest that repeated (>2 episodes) peritonitis has a significant 
impact on T-cell effector capacity based on both in vitro stimulation protocols 
or more direct assessment of function in freshly isolated peritoneal T-cells.
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Figure 5.5 Impact of recurrent peritonitis on T-cell memory phenotype. Paired 
samples of PBMC and peritoneal leukocytes were collected from PD patients (n=21) 
and cells were labelled with fluorescently conjugated monoclonal antibody directed 
against CD4/CD8/CCR7 and CD45R0. A combined gate was set on peritoneal T-cells 
based on CD4 or CD8 expression and their FSC:SSC profiles. For data analysis 
patients were stratified into subsets according to their previous history of peritonitis. The 
data for each subset is presented as box and whisker plots. Overall p values were 
calculated using the Mann-whitney test (see appendix for patient demographics).
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Figure 5.6 Impact of recurrent peritonitis on peritoneal T-regs. Peritoneal 
leukocytes were labelled with fluorescently conjugated monoclonal antibody directed 
against CD3/CD4 and CD25. Cells were subsequently fixed and permeabilized then 
stained with anti-Foxp3. A gate was set on peritoneal T-cells based on their 
FSC/SSC profile and CD3/CD4 expression pattern. CD25 and Foxp3 expression was 
examined within this gated population and the percentage of CD4+/CD25+/Foxp3+ T- 
regs calculated. For data analysis patients were stratified into subsets according to 
their previous history of peritonitis. The data for each subset is presented as box 
and whisker plots. Statistical analysis was performed using the Mann-Whitney test 
(see appendix for patient demographics).
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Figure 5.7 Single telomere length analysis (STELA) of peripheral blood and 
peritoneal T-cells. Samples of peritoneal and peripheral blood leukocytes were 
obtained from PD patients and healthy age-matched volunteers. Highly purified 
(>98%) T-cell populations were isolated by flow cytometry and cell sorting (FACS). 
T-cell telomere lengths were measured by single telomere length analysis (STELA). 
(A) Representative example of STELA data from patient C5. (B) Mean XpYp 
telomere lengths (see appendix for patient demographics).
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We have shown that peritoneal T-cells isolated from the recurrently infected 
cohort had markedly decreased in vitro proliferation and TH1 cytokine 
production. In addition, analysis of Ki67 expression and effluent cytokine 
levels indicates that these cells are indeed potentially hypo-responsive in vivo.
In trying to link peritoneal T-cell function to previous infection, we must 
consider that there are a large number of confounding variables that might 
impact on the analysis. In general the longer you have been on PD therapy 
(vintage), the more likely it is that you will suffer from an episode of infection. 
In spite of this, a stepwise multivariate analysis revealed that only the number 
of previous infections (and not time on PD) was significantly correlated with 
peritoneal T-cell effector function.
Another possible explanation for T-cell dysfunction is that recurrently infected 
patients are a “sicker” population with a higher burden of co-morbid disease 
and increased systemic inflammation (e.g. elevated plasma CRP) that reflects 
their poor outcome on dialysis [4]. By this reasoning, recurrently infected 
patients would also be “systemically unwell” and hence expected to be 
“systemically immuno-deficient”. This is not however what we observed upon 
analysing peripheral blood T-cells from this patient group. Peripheral blood T- 
cells retained their effector function, implying a local specificity of this 
immuno-deficient effect on T-cells localised to the peritoneal cavity. This data 
is perhaps not surprising given the evidence presented in this thesis for the 
phenotypic and functional specificity of peritoneal cavity T-cell populations.
In trying to elucidate the mechanism driving local T-cell hypo-responsiveness, 
we speculated that this effect of peritonitis might be related to global changes 
in T-cell phenotype. Within the memory subsets, the effector memory (TEm) 
sub-sets are “less proliferative” in vitro than naive or central memory (T cm> 
cells [58]. We were not, however able to show that peritonitis resulted in a 
shift towards this T Em phenotype. Our phenotypic analysis does hint that 
recurrent infection (>2) leads to intra-peritoneal accumulation of T-regs. 
Though our experiments did not asses the functional capacity of these T-regs, 
it is tempting to speculate that recurrent infection increases their inhibitory
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function. Previous work in our laboratory has shown that slL-6 R levels and T- 
cell IL-6 R expression are significantly decreased in patients with a past history 
of peritonitis (C Parker, MD thesis). As previously described, IL- 6  signalling 
may be critical to T-cell effector function by allowing cells to overcome T-reg 
suppression. Consequently, defective IL- 6  signalling in the recurrently infected 
cohort may contribute to T-cell anergy by preventing the “T-reg release” 
phenomenon [117]. This facet of T-reg function is currently under 
investigation.
It has been previously suggested in studies of PM0 that the continuous 
drainage of cell from the peritoneal cavity of PD patients contributes to 
significant alterations in phenotype and function. This was believed by some 
authors to potentially contribute to a “burnout” phenomenon that rendered the 
peritoneal cavity compromised in terms of host defence [21]. In the context of 
these studies we also hypothesised that recurrent peritonitis may be driving 
peritoneal T-cells towards cellular senescence so that they are no longer 
responsive to re-stimulation. To further assess this we collaborated with Dr. 
Duncan Baird (Department of Pathology, School of Medicine, Cardiff 
University) to measure peritoneal T-cell telomere lengths.
In the past, analysis of telomere lengths in peritoneal T-cells would have been 
extremely difficult. The most widely used approach, terminal restriction 
fragment (TRF) analysis suffers from a low overall sensitivity and requires 
large cell numbers, making it unsuitable for analysis of the small populations 
such as the peritoneal T-cells [118]. Another widely applied method 
quantitative fluorescence in situ hybridization (Q-FISH) requires metaphase 
chromosomes which restricts analysis to cells that are still proliferating [119]. 
Again this may be unsuitable for poorly proliferating peritoneal T-cells. More 
recently, a technique known as single telomere length analysis (STELA) has 
emerged which overcomes the problems highlighted above. STELA is a 
robust, PCR-based approach that accurately measures the full spectrum of 
telomere lengths from individual chromosomes [87, 8 8 ]. Using STELA we 
were able to compare the telomere lengths between purified peripheral blood 
and peritoneal T-cell populations.
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We observed that peritoneal T-cells from both infection free and recurrently 
infected patients had shortened telomeres compared to peripheral blood, with 
some telomere lengths approaching the senescent range (1-2Kb). This 
significant difference between blood and peritoneal cells can be explained by 
two mechanisms. Either the blood and peritoneal pools are mutually 
exclusive, undergoing cell division at separate rates, or the peritoneum may 
selectively recruit cells which have already undergone numerous cell divisions 
i.e. antigen experienced cells (e.g. memory cells). In truth, both of these 
mechanisms probably occur to some extent. Clearly there is communication 
and transmigration between the two compartments (as proven by our memory 
cell recall response data), however the T-cells with very short telomere 
lengths do not appear to exist in the peripheral blood. These may represent a 
true “resident” T-cell population that have undergone multiple cell divisions 
locally within the PD cavity. In order to survive within the peritoneal cavity, 
these cells must avoid being “flushed out” with each PD exchange; this is 
likely to be achieved by migrating to local peritoneal lymphatic tissue such as 
the milky spots. Within these APC enriched zones the T-cells are likely to 
receive TCR stimulation resulting in localized peritoneal T-cell proliferation. 
Following proliferation these cells are released into the peritoneal cavity and 
may represent the actively proliferating cells detected with Ki67 staining.(see 
figure 5.8).
The shortened telomere lengths may explain in part the generally lower 
responsiveness between peripheral and peritoneal cells as some of the latter 
may have reached cellular senescence.
We also observed that, when compared with healthy age-matched controls, 
our PD patients had considerably shortened peripheral blood T-cell telomere 
length. This telomere shortening may be secondary to the increased 
inflammation and immune stresses that these patients have faced during the 
development of end stage renal failure. Similar telomere shortening has been 
observed in lymphocytes obtained from pre-dialysis and HD patients, 
suggesting that renal failure perse may play some role in the process [1 2 0 ].
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Figure 5.8 Peritoneal T-cell recruitment and re-circulation. T-cells are recruited 
from the peripheral blood into the peritoneal cavity. T-cells re-circulate through 
peritoneal lymph nodes and omental milky spots.
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This may have prognostic implications for PD patients, since previous 
population based studies have shown that in a “normal”, healthy cohort, 
shortened peripheral blood telomere lengths are associated with increased 
mortality. Of note, individuals with shorter peripheral blood telomeres have a 
three-fold increase in cardiovascular mortality and an eight fold higher 
mortality from infectious diseases [1 2 1 ].
In this limited analysis there were however, no significant difference in 
telomere lengths between the patient groups and thus we cannot conclude 
that cellular senescence is the major reason for the decreased peritoneal T- 
cell function seen following recurrent peritonitis. These observations clearly 
need to be followed up in a larger cohort and its relationship to other 
parameters such as time on PD, PD regimen, biocompatibility of fluid 
established.
Though the exact cause of peritoneal T-cell anergy (defined for these 
purposes as a state of unresponsiveness to further stimulation) remains 
poorly defined and is likely multi-factorial and variable between individuals, we 
can predict that it will have profound effects on the host immune system. 
Firstly such patients are “intra-peritoneally” immuno-suppressed which puts 
them at risk of subsequent infection. We have in effect a downward spiral 
whereby infection leads to T-cell anergy, which in turn leads to further 
infection. Secondly, the impaired TH1 response is likely to affect immuno- 
resolution. Previous work in our laboratory has shown that recurrent peritonitis 
is associated on-going production of IL-8 and continued neutrophil recruitment 
during the steady state [47, 52]. We also know that IFN-y (together with IL-6) 
is a pivotal trigger that switches off IL-8 production. Impaired IFN-y production 
by resident T-cells may thus contribute to continued IL-8 production and on­
going neutrophil recruitment [47, 52]. We now have some murine data to 
support this; IFN-y deficient mice clear peritoneal Staphylococcal infection 
much more slowly than wild type mice, which is paralleled by impaired 
neutrophil trafficking [Topley, Jones, unpublished data].
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5.4 Conclusion
These data suggest that recurrent infection has a negative impact on 
peritoneal T cell effector function. Peritoneal T cells isolated from patients 
who have suffered multiple episodes of peritonitis display impaired 
proliferative capacity and TH1 effector function. The impaired TH1 function is 
not the result of a switch in T-cell polarisation as the cells also display 
impaired IL-4 and IL-17 production. Although peritoneal T-cells have 
shortened telomere lengths, this is not apparently related to recurrent 
peritonitis but may nevertheless confer a more general susceptibility to 
infection. Regardless of the mechanism, the impaired T-cells responses are 
likely to result in both increased risk of infection and impaired immuno- 
resolution, both of which will likely contribute to membrane damage and 
treatment failure.
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Chapter 6 
General Discussion
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Since its introduction more than 30 years ago, PD has been beset by 
infectious complications. Despite improvements in connection techniques 
(particularly the introduction of disconnect Y-set systems) and patient 
education, peritonitis rates remain unacceptably high and still contribute 
significantly to treatment failure. More worryingly over the past decade there 
has been a shift in the spectrum of organisms causing infection with an 
increased incidence of Gram-negative peritonitis which usually has a worse 
clinical course and is associated with higher mortality and technique failure 
[112, 113] (Table 6.1).
Species
% Non­
resolved 
infections
% Catheter 
removals
% Patient 
deaths
Gram-positive 12.7 4.8 1.4
Staphylococcus,
Streptococcus 12.7 4.7 1.4
Gram-negative 36.4 16.6 3.7
E. coli,
Enterobacter 25.0 5.8 2.9
Pseudomonas,
Serratia,
Klebsiella
62.5 37.0 7.4
Table 6.1 Morbidity and mortality in bacterial peritonitis [112, 113].
It is apparent that for PD to thrive as a treatment modality, we must develop a 
better grasp of the basic disease processes that lead to structural and 
functional changes in the peritoneal membrane. In particular we need to 
understand the fundamental processes that link repeated inflammation with 
tissue fibrosis and treatment failure.
To date, most studies of the peritoneal immune system have focussed on the 
early stages of peritonitis, the biology and phenotype of the peritoneal
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macrophage and the role of the peritoneal mesothelial cells in regulating 
peritoneal immunity and responses to infection [33-41]. Although these 
analyses have provided significant insight into our understanding of the 
peritoneal immune responses, to date the contribution of the peritoneal T-cells 
to the processes that regulate inflammation and resolution have received 
much less attention particularly in studies of PD.
Recent years have seen an exponential increase in the number of 
publications based on T-cell research. This has largely been fuelled by the 
interest in the newly identified subsets such as T-regs, TH17 and memory cell 
phenotypes. Most of this research centres on animal models of disease so 
that there continues to be a paucity of human data, especially data derived 
from human peripheral tissue T-cells. The peritoneal cavity of PD patients, 
with its continuous access (via the indwelling catheter) presents a unique 
opportunity to study human T-cell phenotype, activation status and 
contribution to local immunity during both stable dialysis and during episodic 
infection. The aim in undertaking this research was to develop a better 
understanding of the basic phenotype and reactivity pattern of peritoneal T- 
cells so that the impact of recurrent peritonitis on the behaviour of these cells 
could be assessed in the context of global peritoneal immunity.
Previous studies of peritoneal T-cells have been somewhat contradictory with 
some suggesting that the cells are primed and activated while others suggest 
that they are anergic and unlikely to respond to stimulation [8 , 45-48, 70, 104, 
114, 121, 136]. In view of this we commenced our studies by analysing the 
activation status and reactivity profile of resident peritoneal T-cells. Our 
studies revealed that although peritoneal T-cells expressed markedly 
increased levels of CD69, this was not matched by a corresponding increase 
in CD25. Indeed, the small increase in peritoneal CD25 levels is likely due to 
the expression of this molecule by T-regs rather than by activated T-cells. 
From this we can conclude that CD69+ peritoneal T-cells are not completely 
activated, a factor that suggests that either they are in a state of partial 
activation or they represent the peritoneal equivalent of the recently described
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CD69+ “adaptive regulatory T-cells” which are characteristic of chronic 
inflammatory diseases such as lupus or RA [96].
We next investigated the reactivity of these cells, concentrating first on their 
cytokine expression profile. We have shown that during both the steady state 
and during peritonitis, the peritoneal T-cells are skewed toward a TH1 polarity. 
The TH1 response generated serves a dual purpose, not only does it enhance 
macrophage bacterial clearance, it also promotes immuno-resolution by 
promoting neutrophil apoptosis through IL-6 /slL-6 R dependent mechanisms 
[47, 52]. This localised TH1 bias is likely to be driven by peritoneal DC 
derived signals such as IL-12 [26, 27, 55].
The influence of DC on T-cell reactivity was further emphasised by our 
analysis of peritoneal T-cell proliferation. We were able to demonstrate that 
the proliferation of peritoneal T-cells cells (in vitro) requires co-stimulation 
from APC [26, 27, 55]. This co-stimulation occurs via both cell-cell contact 
dependant mechanisms and also via the production of soluble mediators 
which. This intimate dependence on APC was in contrast to peripheral blood 
T-cells that appear much less reliant on APC for their proliferative responses 
in vitro. Thus we conclude that peritoneal T-cells have a much higher 
activation/proliferation threshold than peripheral blood T-cells. This may 
serve as a control mechanism to limit activation of these cells in the peritoneal 
cavity.
Having focussed on peritoneal T-cells obtained during infection-free PD, we 
next examined the proliferative capacity of peritoneal T-cells isolated during 
peritonitis. The complex mechanisms that govern effector T-cell clearance 
during acute inflammation are poorly defined, however it is accepted that 
effector cells have a propensity to survive and that elimination of these cells is 
an instructional rather than a default process [97, 106]. Our analysis of 
peritoneal T-cell:APC interaction during peritonitis has provided us with further 
insight into the regulation of this process. We discovered that peritoneal APC 
inhibit proliferation and induce apoptosis in the recruited T-cell population. 
This mechanism may serve to promote immuno-resolution, minimising host
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damage by preventing the accumulation of highly activated but now 
redundant effector cells.
Having established their reactivity profile, we next investigated whether the 
peritoneal T-cell pool has a memory component. Antigen specific memory 
defines the adaptive immune response, protecting the host during re­
exposure to previously encountered foreign antigen. Our results have clearly 
demonstrated that the peritoneal cavity is enriched in cells displaying an 
effector memory phenotype. This observation is in agreement with the current 
paradigm of T-cell memory and is likely explained by the pro-inflammatory 
chemokine receptor profile expressed by this subset of cells [79]. Our 
functional analysis showed that these memory cells mount a potent TH1 
skewed recall response to Tuberculosis, Influenza antigen and Tetanus 
Toxoid. This implies that circulating memory cells are selectively recruited 
into the peritoneal cavity from their sites of formation, forming a first line of 
defence at peripheral sites. In addition, our analysis of the TCRVp repertoire 
suggests that Staphylococcus aureus peritonitis may result in the local 
polyclonal expansion of peritoneal cells, so that at least some memory may be 
formed locally.
Further insight into the dynamics of T-cell trafficking was obtained from our 
analysis of T-cell telomere lengths. Though the term “resident peritoneal cell” 
is often used to describe cells obtained from PD effluent, this term is 
misleading since a T-cell recruited from the blood into the cavity then drained 
off minutes later would still be classed as a resident peritoneal cell. It could 
be argued that resident peritoneal T-cells do not in fact exist, and that cells 
obtained in PD effluent are continually trafficking between blood, PD fluid and 
peritoneal lymphatics. Until now it has been very difficult to disprove this 
argument since cell labelling studies may be logistically difficult to perform in 
humans. Our telomere data allows us to argue that there may in fact be a 
truly resident peritoneal T-cell population that resides and divides locally 
within the peritoneum. The evidence supporting this comes from the finding 
that T-cells with very short telomere lengths were found only in the 
peritoneum but not in the peripheral circulation. Had these cells been
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recruited from the blood then we would have seen a corresponding telomere 
band in the peripheral blood, but this is not in fact the case. These cells are 
likely to have entered the peritoneum from the blood, and undergone further 
cell division locally. They are “truly resident” cells, which may avoid being 
drained off by adhering to the peritoneal membrane or trafficking to local 
lymph tissue. Thus we conclude that “resident peritoneal T-cells” are likely to 
consist of a mixture of truly resident cells that remain within the local 
environment and cells that are constantly re-circulating between blood, 
peritoneum and draining lymph nodes. It is tempting to speculate that the 
local cells (with shorter telomere lengths) represent the long-lived effector 
memory pool whereas the re-circulating cells are central memory or naive 
cells.
From our studies it is becoming clear that the peritoneal T-cell pool contains a 
sophisticated functional effector arm capable of initiating/propagating a potent 
immune response. This response must be tightly controlled, since an 
overactive response will likely result in host damage. The human body has 
developed numerous strategies that serve to regulate this process and 
minimise self-harm. Chief amongst these regulatory mechanisms are the 
specialised T-cell subset known as T-regs [72-74]. Though most T-reg 
studies have focused on the role that they play in autoimmune diseases, there 
is now an abundance of data to suggest that they also regulate host 
responses to infection. This is exemplified by the analysis of murine 
Pneumocystis carinii infection. Infection of RAG2 mice (which are deficient in 
T and B cells) normally results in very little tissue damage. Concomitant 
transfer of effector T-cells into this population results in a florid pneumonitis 
rapidly followed by death. Transfer of T-regs can prevent this pneumonitis by 
dampening down the immune response and restoring homeostasis [122, 123].
We have shown for the first time that the human peritoneal cavity is 
specifically enriched in Foxp3+ T-regs that display potent suppressive function 
mediated via cell-cell contact and (to a lesser extent) via production of soluble 
mediators (IL-10 and TGFp). We speculate that during the non-infected state, 
peritoneal T-regs maintain the integrity of the host tissue by minimising non­
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specific immune responses to innocuous antigens or host flora. This 
suppression is likely to occur via production of IL-10 and TGFp within the 
cavity itself (where direct cell-cell contact is less likely), while cell-cell contact 
suppression may occur within the draining nodes where T-regs, effector 
leukocytes and DC are in close proximity. In this way T-regs are critical in 
maintaining homeostasis. This contrasts somewhat with the situation that 
occurs during peritonitis, where T-reg activity may be seen as 
counterproductive, preventing the host from mounting an adequate immune 
response, in effect protecting the pathogen. To prevent this, DC derived 
cytokines (in particular IL-6 ) allow effector T-cells to overcome T-reg 
suppression and amplify the inflammatory response [117].
Given the likely importance of peritoneal T-regs as “peace keepers” within the 
pro-inflammatory milieu of the peritoneal cavity, it is evident that any 
manipulation in the function of these cells may have consequences for the 
host. Strategies aimed at enhancing T-reg number or activities have shown 
promise in reducing chronic inflammation in animal models [124]. Conversely, 
strategies that deplete the T-reg population are likely to exacerbate any 
underlying inflammation. This would be a clear benefit in oncology where T- 
reg suppression may be protecting the tumor from the host immune defences 
[124]. T-reg depletion may also inadvertently occur with commonly used 
immunosuppressive regimens. Since T-regs are highly dependant on IL-2 for 
their function and survival, treatments that target effector T-cells via this 
pathway (e.g. anti-CD25 and calcineurinin inhibitors) may inadvertently 
disable T-regs [125, 126]. Here we can speculate as to the pathogenesis of 
post transplant encapsulating peritoneal fibrosis. This paradoxical increase in 
peritoneal inflammation and fibrosis in spite of immunosuppression may 
reflect selective peritoneal T-reg depletion, which unmasks a “primed” pro- 
inflammatory peritoneal response.
Closely linked to T-regs, but displaying divergent function are the highly pro- 
inflammatory TH17 sub-set. The role of TH17 cells in regulating the host 
response to microbial infection remains poorly defined. This is surprising
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given that most authors agree that the TH17 lineage evolved to manage 
infections not dealt with adequately by the TH1/TH2 responses [62-65].
TH17 development is driven by IL- 6  and TGFp. Since both these cytokines 
have been identified in the inflamed peritoneal cavity we hypothesised that 
TH17 cells would also be present in the inflamed peritoneum [127, 128]. Of 
the fifteen patient effluent samples analysed using flow cytometry we were 
only able to detect a convincing population of TH17 cells in two, both of whom 
had suffered prolonged or severe peritoneal inflammation. That we were not 
able to detect these cells in the majority of peritonitis patients suggests that 
they are subject to tight regulation presumably aimed at limiting both their 
number, activity and their potential for host damage. We speculate that 
prolonged or severe peritoneal inflammation (particularly with S aureus or 
Gram-negative organisms) leads to a breakdown in this equilibrium leading to 
the persistence of TH17 cells and on-going inflammation
Although we had difficulty isolating these cells ex vivo, the elevated IL-17 
levels detected during peritonitis would suggest that these cells might be 
present (albeit in very low numbers) at an early phase of peritonitis. During 
this early phase they may promote neutrophil recruitment, as evidenced by 
previous studies demonstrating that IL-17 induces CXC chemokine production 
by HPMC [109, 111].
The final peritoneal T-cell subset that we investigated was the Vy962 subset 
(the so called gamma/delta T-Cells). These are a unique T-cell population 
similar in many respects to activated DC [75-78]. Previous studies have 
suggested that, unlike conventional ap T-cells, Vy952 T-cell participate in the 
early “innate” immune responses. In accordance with this, we have shown 
that Vy962 T-cells are recruited early during the course of peritonitis, peaking 
at day 1-2 (as compared to ap T-cells that peak between days 4-6 depending 
on infection type). We were also able to show that these cells are selectively 
activated by HMB-PP, a highly conserved metabolic by-product produced by 
most Gram-negative species (but not Staphylococcal spp.). This observation
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might explain why effluent from Gram-negative patients is able to activate 
Vy962 T-cells.
Since Vy962 T-cells have potent APC function we predict that similar to DC, 
they form a pivotal link between the innate and adaptive arms of the 
peritoneal immune response. Elucidation of the role of these cells in Gram- 
negative infection is of very significant importance given the high morbidity 
and mortality associated with these types of infections in PD patient [112, 
113].
Data presented in this thesis has shown that the peritoneal T-cell population is 
a heterogeneous mixture of specialised subsets, with unique but interacting 
effector functions. These cells must exist in a controlled equilibrium in order to 
both maintain homeostasis and mount an effective immune defence. A 
paradigm of peritoneal inflammation incorporating our data on the phenotype 
and reactivity patterns of peritoneal T-cells is outlined in Figure 6 .1-6.4.
We concluded our studies by assessing what impact recurrent infection had 
on the peritoneal T-cell population. Peritoneal T-cells isolated in the steady 
state from patients who had suffered > 2  episodes of peritonitis showed 
markedly impaired ex vivo proliferation and effector function and appeared to 
have reached a state of adaptive tolerance (in vivo anergy). We speculate that 
increased T-reg numbers and function (possibly enhanced by the loss of IL-6  
signalling) contribute to this anergic state, other plausible explanations such 
as impaired DC signalling remain unexplored and may also play a significant 
role.
Whatever the exact mechanism, this peritoneal T-cell anergy is likely to 
contribute to a state of immuno-suppression thus rendering the patients likely
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Figure 6.1 Peritoneal immune system homeostasis. Effector memory T-cells reside 
primarily within the peritoneal cavity, maintained by local anti-apoptotic and proliferative 
signals (IL-7 and IL-15). Central memory cells re-circulate through the peritoneal 
lymphatic system “patrolling” for antigen loaded DC. T-regs maintain homeostasis via 
production of suppressive cytokines within the peritoneal cavity and via contact 
mediated suppression within the lymph nodes.
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Figure 6.2 Early phase of peritonitis. Invading pathogens are ingested by phagocytic 
cells, including peritoneal macrophages (PM0) and HPMC. Pathogen derived peptides 
are displayed on MHC class II molecules to the “resident” effector memory population. 
Antigen recognition is followed by an immediate TH1 polarised cytokine response. The 
IFN-y thus generated stimulates macrophage bacterial killing. Concurrently HPMC 
derived cytokines lead to recruitment of “early phase” cells including neutrophils, Vy952 
T-cells and TH17 cells. Interleukin17, IL-1 and TNFa promote further neutrophil 
recruitment by inducing HPMC production of CXC-chemokines. Immature peritoneal 
DC and Vy962 T-cells are activated and migrate to local lymph nodes as “professional” 
APC. DC and HPMC derived IL-6 serves to inhibit T-reg suppression allowing 
inflammation to proceed.
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Figure 6.3 Late phase of peritonitis. IL-6 trans-signalling orchestrates a switch from 
neutrophil to mononuclear cell recruitment. Recruited T-cells are activated by 
peritoneal APC including macrophages, DC and HPMC. Activated APC (DC and Vy96 
2) present antigen to central memory T-cells within the peritoneal lymph nodes, thus 
generating a wave of antigen specific effectors.
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Figure 6.4 Immuno-resolution. Following prolonged APC stimulation, recruited T-cells 
undergo activation induced cell death. Cells that survive this process remain in the 
peritoneum as long-lived memory cells. As inflammation subsides, IL-6 levels falls, thus 
unmasking peritoneal T-reg suppression and restoring homeostasis.
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Figure 6.5 Chronic inflammation. Recurrent peritonitis results in peritoneal T-cell 
anergy and a defective TH1 response. Together with impaired IL-6 signalling, this leads 
to on-going neutrophil recruitment and impaired cellular immunity. This generates a 
chronic inflammatory milieu within the peritoneal cavity that contributes to membrane 
fibrosis and treatment failure.
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more susceptible to further episodes of peritonitis. It is also likely to have a 
negative impact on immuno-resolution and contribute to neutrophil retention 
and on-going inflammation (Figure 6.5). This speculation is now confirmed by 
more recent work in our laboratory showing that IFN-y deficient mice display 
significantly impaired bacterial clearance and aberrant neutrophil trafficking.
From our studies we can conclude that T-cell dysregulation may be a pivotal 
event in the early stages of chronic inflammation, less clear however is the 
mechanism that links dysregulated inflammation to tissue fibrosis. This thesis 
has not directly addressed this issue, however here is an abundance of 
animal model and in-vitro data to suggest that inflammation can trigger 
fibrosis, indeed our own group have demonstrated that recurrent inflammation 
is associated with membrane fibrosis in the murine model of peritonitis.
The role of T-cells in the genesis of fibrosis remains poorly defined however, 
with conflicting reports of pro or anti-fibrotic effects depending on the local 
environment and cytokine milieu [129]. This is exemplified by murine studies 
of pulmonary fibrosis. Athymic (nude) mice (with a total lack of T-cells) 
continue to develop pulmonary fibrosis in response to bleomycin, suggesting 
that T-cells play no role in the process [130]. In contrast mice deficient in 
CD28 signalling (a central T-cell co-stimulant) appear protected against 
bleomycin-induced fibrosis. Transfer of CD28+ T-cells into these mice restores 
a normal “fibrotic” response suggesting causality [131]. A further study has 
shown that exposure of SCID mice (that lack functional T-cells) to asbestos 
results in more fibrosis (than wild type), suggesting that in this case T-cells 
are protective [132]. These conflicting results may reflect the “immune- 
adaptation” that may occur in genetically modified mice, it may also reflect the 
complex, often divergent functions of T-cells in-vivo. In the context of our 
studies, it is interesting to note that T-cell derived IFN-y has been identified as 
an extremely potent anti-fibrotic factor, capable of inhibiting fibroblast 
proliferation and collagen production [133, 134]. This hints that loss of TH1 
effector function (as seen following recurrent peritonitis) may contribute 
directly to peritoneal membrane fibrosis.
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We must now consider the therapeutic options that will allow us to reverse or 
at least limit the detrimental impact of recurrent infection on peritoneal 
immune homeostasis. Over the last century the approach to combating 
infectious disease has focussed almost entirely on killing the invading 
pathogen with antibiotic therapy. The development of multiple-drug-resistant 
bacteria and the recognition that recurrent infection is linked to chronic 
inflammation highlights the need for a novel strategy to deal with microbial 
infections. Such an “immuno-modulatory” strategy may focus on enhancing or 
suppressing the immune response, aiming to restore “normality”. With regard 
to the peritoneal immune system, such strategies may include augmenting 
IFN-y (°r IL-6 ) signalling or manipulating T-reg activity to alter the magnitude 
of the inflammatory response (Figure 6.6)[135]. Alternative approaches 
include taking advantage of the adaptive immune response and priming the 
peritoneal memory T-cells with vaccines targeted against the most common 
infective agents. Though previous attempts at vaccination have been 
unsuccessful [81, 136], these trials pre-dated our current understanding of T- 
cell biology. As we have shown, we are now able to assess the efficacy of a 
potential vaccine in generating functional peritoneal memory cells. Moreover, 
we may soon be able to modulate T-cell signalling pathways and B-cell help 
thus enhancing antibody responses.
The biggest challenge in designing novel immuno-modulators is the 
complexity of the human immune system itself. This highly refined system 
does not lend itself well to a “shotgun approach”, highlighting the need for a 
better understanding of the fundamental processes involved in tissue 
inflammation. We hope that further studies such as this may lead to the 
development of novel immunotherapeutic agents that prevent or reverse the 
processes that drive dysregulated inflammation.
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Figure 6.6 Strategies for modifying the acute inflammatory response [135]
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6.2 Future work
The aim of our research was to undertake an extensive, contemporary 
analysis of the peritoneal T-cell repertoire rather than to focus specifically on a 
particular T-cell subset. Clearly many of the studies are limited by both their 
cross sectional nature and by the small number of patients involved. In spite 
of this, our findings have provided us with novel insights into the behaviour of 
human peripheral tissue T-cells, allowing us to focus future research on those 
aspects of peritoneal T-cell biology that appear important or linked to disease. 
Current or future avenues of peritoneal T-cell research include: -
• The role of peritoneal Vy962 T-cells in bacterial peritonitis: Based 
on data presented in this thesis we (in collaboration with Dr Matthias 
Eberl and Professor Bernhard Moser, Cardiff university department of 
medical Biochemistry) have been awarded a Welsh Office of Research 
and Development grant (£170,000) to study the role of Vy9S2 T-cells in 
PD peritonitis. Though the study is primarily a mechanistic analysis of 
peritoneal Vy9S2 T-cells, it will also provide insight into the trafficking of 
TH17, T-regs and memory T-cells during acute inflammation.
• The impact of recurrent infection on peritoneal T-reg function. 
Though our studies assessed the impact of recurrent infection on 
effector T-cell function, we did not investigate the impact of infection on 
T-reg function. We hypothesise that recurrent infection leads to 
increased T-reg activity, which may have a suppressive effect on local 
effector cells. This is the focus of current research.
• Characterise the function of CD69+ peritoneal T-cells. We have now 
begun to characterise the function of FACS sorted CD69+ peritoneal T- 
cells. Preliminary data suggests that these cells suppress peripheral 
blood T-cell proliferation, suggesting that they may indeed perform a 
regulatory role within the peritoneum. Further research is warranted to 
confirm and expand on these findings.
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• Explore potential vaccination strategies. Our data shows that the 
peritoneal cavity is enriched in memory T-cells. Future research should 
focus on whether these cells can be primed to target common invading 
pathogens.
• T-cell telomere length studies. PD patients appear to have 
shortened telomere lengths, which may be associated with increased 
morbidity and mortality. This could be evaluated further in a larger 
prospective study. The impact of more biocompatible fluid on peritoneal 
T-cell telomere shortening could also be assessed.
• Investigate the role of T-cells in peritoneal fibroblast 
activation/myofibroblast differentiation. Future research may focus 
on the mechanisms by which T-cell activation may initiate or propagate 
tissue fibrosis.
• Characterise the phenotype and function of peritoneal T-cells 
obtained from “healthy” individuals e.g. women undergoing 
laparoscopic sterilisation.
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Appendix I: Tablel Patient demographics
Patient Age Peritonitis
episodes
DM
(Y/N)
KT/V
renal
KT/V
PD
KT/V
Total
Alb Wt
(Kg)
UF Glucose
exposure
(g/day)
Transport 
Status *
PD
Vintage
(months)
Extraneal
(Y/N)
Aetiology
Of
ESRF **
Outcome 
at study 
end
A1 66 0 N 1.23 1.08 2.31 33 55 1.26 108 H 4 N Hypertensive
nepropathy
CAPD
A2 58 0 Y 1.15 1.15 2.3 39 81 0.66 108 LA 4 N Hypertensive
nepropathy
CAPD
A3 66 0 Y 0 2.11 2.11 36 62 1.75 99.8 HA 17 Y Systemic
sclerosis
CAPD
A4 66 0 Y 0.13 2.03 2.17 35 60 2.22 127 LA 37 N Diabetic
nephropathy
CAPD
A5 42 0 N 0 1.72 2.06 35 77 1.55 154.2 HA 10 Y Unknown CAPD
A6 59 0 N 0.35 2.39 2.81 41 53 1.73 127 HA 86 N Chonic
pyelonepritis
CAPD
A7 75 0 N 0.4 1.78 2.18 34 72 1.75 81.6 HA 40 Y Reflux Transplant
AS 66 0 N 0.5 1.14 1.65 32 74 0.08 108 HA 13 N Unknown CAPD
A9 46 0 Y 0.41 1.6 2.01 32 62 2.71 99.8 HA 12 Y Unknown CAPD
A10 36 0 N 0.54 1.05 1.59 38 97 2.43 81.6 HA 12 Y Unknown CAPD
A11 57 0 Y .0 1.59 1.59 37 59 1.81 108 LA 24 N Interstitial
nephritis
R.I.P
A12 59 0 N 0.6 1.62 2.22 39 80 1.0 108 HA 3 N Focal
segmental GN
CAPD
B1 71 1 N 1.1 1.31 2.4 39 88 2.2 81.6 HA 22 Y Unknown CAPD
B2 65 1 N 2.01 0.81 2.76 36 63 0.83 81.6 LA 11 N Reflux CAPD
B3 62 1 N 3.44 1.34 4.78 37 81 2.35 154 HA 9 Y Renovascular
disease
CAPD
B4 64 N 0 1.64 1.64 38 62 1.00 127 H 48 N Unknown HD
B5 56 1 N 0.56 1.32 1.88 31 71 1.71 108 LA 4 N IgA GN CAPD
B6 79 N 0.46 2.07 2.53 35 78 1.48 81.6 HA 15 Y Diabetic
nephropathy
CAPD
B7 70 1 Y 0.98 1.72 2.7 35 86 3.05 99.8 HA 16 Y Diabetic
nephropathy
R.I.P
B8 60 1 Y 1.25 1.47 2.72 35 73 3.19 81.6 HA 22 N APCKD CAPD
B9 68 N 0.09 1.43 1.52 28 56 0.32 81.6 H 132 Y Analgaesic
nephropathy
R.I.P
B10 66 1 N 2.21 1.61 3.81 38 62 1.9 108 HA 6 N Unknown CAPD
B11 62 1 N 0 3.03 3.03 42 36 2.10 81.6 H n N Chonic
pyelonepritis
CAPD
B12 61 1 Y 1.45 0.73 2.18 37 103 1.99 108 N/A 5 Y Nephrectomy, 
Ca kidney
CAPD
B13 70 1 N 1.26 1 2.16 32 83 0.85 127 HA 48 N Membranous
GN
CAPD
B14 41 1 Y 1.6 0.93 2.53 40 103 1.83 81.6 HA 6 Y Unknown CAPD
B15 35 1 Y 0 2.87 2.87 34 66 1.10 113.6 HA 24 N Unknown CAPD
B16 74 1 Y 1.4 1.06 2.46 42 74 0.6 113.6 H 18 N Unknown CAPD
B17 40 1 N 0 1.72 1.72 32 65 0.61 81.6 HA 72 N Mesangio 
capillary GN
CAPD
B18 42 1 N 0.61 1.6 2.21 36 80 1.5 81.6 H 38 Y Hypertensive
nepropathy
CAPD
B19 78 N 0.8 1.03 1.83 34 71 1.3 108 LA 36 N CLL R.I.P
B20 75 1 N 1.0 1.83 2.83 21 51 0.5 126.4 HA 18 N Diabetic
nephropathy
CAPD
B21 66 1 Y 0 2.11 111 36 62 1.75 99.8 HA 17 Y Systemic
sclerosis
CAPD
B22 65 1 N 0 2.11 2.11 36 62 1.75 99.8 HA 17 N Hypertensive
nepropathy
CAPD
B23 40 1 N 0.52 1.6 2.12 39 68 0.45 127 HA 36 N GN CAPD
B24 39 1 M 0 2.43 2.43 39 77 1.0 81.6 HA 29 Y Unknown CAPD
C1 66 3 N 0.13 1.78 1.91 33 61 0.46 113.6 HA 70 Y IgA GN HD
C2 74 5 N 0 2.12 2.12 32 56 1.1 127 HA 72 N Hypertensive
nepropathy
CAPD
C3 71 5 N 0.86 1.25 2.11 27 82 1.3 81.6 H 24 Y Diabetic
nephropathy
R.I.P
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Patient Age Peritonitis
episodes
DM
(Y/N)
KT/V
renal
KT/V
PD
KT/V
Total
Alb Wt
(Kg)
UF Glucose
exposure
(g/day)
Transport
Status*
PD
Vintage
(months)
Extraneal
(Y/N)
Aetiology
Of
ESRF **
Outcome 
at study 
end
C4 57 5 N 0 1.89 1.89 36 63 0.9 93 H 89 Y Obstructive
uropathy
R.I.P
(EPS)
CS 64 6 N 0.99 1.12 2.11 38 72 0.38 163.4 HA 60 N Renowascular
disease
R.I.P
C6 50 5 N 0.5 2.13 2.63 37 78 1.7 0.36 LA 8 N IgA GN Transplant
C7 79 5 N 0.58 1.36 1.92 30 68 0.41 36 HA 36 Y Unknown R.I.P
C8 75 4 N 0.3 1.64 1.99 36 79 1.07 127 HA 60 Y IgA GN CAPD
C9 67 4 Y 1 0.85 1.85 32 55 0.7 127 H 47 Y Diabetic
nephropathy
CAPD
C10 69 6 N 0 1.52 1.52 28 56 0.32 81.6 H 143 Y Interstitial
nephritis
R.I.P
C11 43 1 Y 0 2.37 2.37 33 70 2.25 99.4 H 120 Y Chronic
peylonephrtits
CAPD
C12 79 3 Y 0.5 1.75 2.25 21 63 1.9 81.6 HA 24 Y Diabetic
nephropathy
R.I.P
C13 38 3 Y 0 0 2.31 30 70 0.4 113.6 H 117 Y unknown R.I.P
(EPS).
Group A - 0 peritonitis episodes *H-High
GrouD B - 1-2 Deritonitis eDisodes HA-high average **GN- Glomerulonephritislaroup a  i  z periionitis episoaes la-low average APKD- Adult polycystic
Group C - >2 peritonitis episodes L_Low s kidney disease
EPS- Encapsulating 
peritoneal sclerosis
Appendix I: Table 2 Peritonitis data for group B patients
B1 a) Coag. neg Staph. May 05
B2 a) Coag. neg Staph. Feb 07b) Staph. Aureus Feb 07
B3 a) Coag. neg Staph. Aug05
B4 a) Staph. Aureus May 06b) Staph. Aureus Nov 07
B5 a)Coryneforms Jan 05
B6 a) Coag. neg Staph. Mar 06b) Coag. neg Staph. Apr 06
B7 a) E.Coli Aug 06
B8 a) Staph. Aureus Sep 06
B9 a) Coag. neg Staph. Apr 03b) Coag. neg Staph. May 05
B10 a) Coag. neg Staph. Aug 05
B11 a) E.Coli Feb 08
B12 a) Bacteroides Aug 07
B13 a) E.Coli Jun 07
B14 a) a Haem. Strep May 07
B15 a) Coag. neg Staph. Aug 07
B16 a) Coag. neg Staph. Oct 07
B17 a) Coag. neg Staph. May 03b) Coa.g. neg Staph. Oct 07
B18 a) Staph. Aureus Apr 06
B19 a) a Haem. Strep Jun 05b) E.Coli Aug 05
B20 a) Coag. neg Staph. Feb 08
B21 a) E.Coli Oct 06
B22 a) E.Coli Mar 08
B23 a) Coag. neg Staph. Oct 08
B24 a) Coag. neg Staph. Mar 08
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Appendix I: Table 3 Peritonitis data for group C patients
C1
a) Coag. neg Staph. Feb 06
b) Coag. neg Staph. Apr 06
c) Coag. neg Staph. Jun06
C2
a) Coag. neg Staph. Jan 03
b) Coag. neg Staph. Aug 03
c) Coag. neg Staph. Feb 06
d) Coag. neg Staph. Mar06
e) Coag. neg Staph. May 06
C3
a) Coag. neg Staph. Jan 06
b) Coag. neg Staph. Mar 06
c) Coag. neg Staph. Nov 06
d) Staph. Aureus Dec 06
e) Coag. neg Staph Mar 07
C4
a) Coag. neg Staph. Jan 00
b) Coag. neg Staph. Apr 04
c) Coag. neg Staph. Nov 05
d) Coag. neg Staph. Feb 06
e) Neisseria Mar07
C5
a) Coag. neg Staph. Feb 02
b) Coag. neg Staph. Nov 03
c) Coag. neg Staph. Dec 03
d) Coag. neg Staph. Jan 04
e) Coag. neg Staph. Feb 04
f) a haem. Strep Feb 05
C6
a) Corynebacterium Aug 06
b) Corynebacterium Nov 06
c) Corynebacterium Jan 07
d) Corynebacterium Aug 07
e) Corynebacterium Sep 07
C 7
a) Coag. neg Staph. Aug 04
b) Coag. neg Staph. Dec04
c) Coag. neg Staph. Jan04
d) Coag. neg Staph. Apr 04
e) Coag. neg Staph. Aug 04
C8
a) Coag. neg Staph. Jan 00
b) Coag. neg Staph. Apr 04
c) Coag. neg Staph. Nov 05
d) Coag. neg Staph. Feb06
C9
a) Coag. neg Staph. Aug 05
b) Coag. neg Staph. Nov 06
c) Enterococcus Feb 07
d) a Haem. Strep Aug 07
C10
a) Coag. neg Staph. Apr 03
b) Coag. neg Staph. May 05
c) Coag. neg Staph. Jan 07
d) Coag. neg Staph. Feb 07
e) Coag. neg Staph. Apr 07
f) Coryneforms Oct 07
C11
a) St Aureus Mar 03
b) Coag. neg Staph. May 03
c) Coag. neg Staph. Jan 04
d) Coag. neg Staph. Jan 08
e) Coag. neg Staph. Jan 08
C12
a) Coag. neg Staph. May 04
b) Coag. neg Staph. Nov 04
c) Coag. neg Staph. May 05
C13
a) Staph. Aureus. Nov 98
b) Coag. neg Staph. Oct 04
c) Coag. neg Staph. Jan 07
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AppendixII: Table 1 Patients used in each figure
Chapter 2
Figure 2.1 Representative example from A8
Figure 2.2 Representative example from B12
Figure 2.3 Representative example from B14
Figure 2.4 Representative example from B14
Figure 2.5 (A) Representative example from B3 
(B) Representative example from A5
Chapter 3
Figure 3.1 (A) Representative example from A9 of data obtained from ..
Figure 3.2 See figure for patient data
Figure 3.3 Data derived from 5 healthy controls
Figure 3.4 Representative example shown from B14 of data derived from 
B14, B12, A4, A9 and A5.
Figure 3.5 (A) Data derived from A2, A6, A4, A5, B6t C3, B8, A11
(B) Data derived from B14, B15, B16, B17, B21, B22, B23, B24,
C10 and C9.
Figure 3.6 (A) Data derived from A7, A8, A5, B10 and A11.
(B) Representative example shown from A7 of data derived from 
A7, A8 and A5.
Figure 3.7 (A) Data derived from C12, A7 and A5.
(B) See figure for patient data.
(C) Data derived from A7.
(D) Representative example shown from B14 of data derived from 
B14 and A9.
Figure 3.8 See figure for patient data
Figure 3.9 See figure for patient data
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Chapter 4
Figure 4.1 (A) Representative example from A7 (B) Data derived from A1, 
B1, A3, B12, A4, A5, B6, C1, C2, A7, C3, B8, A8, A10, A11.A6, 
A7, C3, B21 and C4.
Figure 4.2 Representative example from B11 of data derived from B11, C3, 
A7 and B7.
Figure 4.3 Representative example from A6 of data derived from A6, B3,
A7 and B6.
Figure 4.4 Data derived from
Figure 4.5 Representative example shown from A5 of data derived from A5, 
B14, A1, A12 and A11.
Figure 4.6 (A) Data derived from A2, A6, A4, A5, B6, C3, B8 and A11.
(B) Data derived from B14, B15, B16, B17, B21, B22, B23, B24, 
C10, and C9.
Figure 4.6 Data derived from A12, A9 and B12.
Figure 4.7 (A) Representative example shown from A10 of data derived from 
A10, A7, A11, A5 and A1.
(B) Representative example shown from C3 of data derived from 
C9, C3.B3, C2, C1, B10, C3, C1, B6, and C10.
(C) Representative example shown from B4 of data derived from 
B4, B8 and B14.
Figure 4.8 (A) Representative example shown from A1.
(B) Data derived from A1, A2, B4, B5, A5, B6, C1, C2, A6, A6, B7 
and C4.
Figure 4.9 (A) See figure for patient data.
(B) Data derived from A1, A11 and B14.
Figure 4.10 (A) See figure for patient data.
(B) See figure for patient data.
Figure 4.11 (A) Representative example from B21 of data derived from B21 
and C1(a).
(B) See figure for patient data.
Figure 4.12 (A) Data derived from A9
(B) Data derived from A11
(C) Data derived from B6
(D) Data derived from B12, A9, B9, B16.B14, C11, B22, B20
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Figure 4.13 Gram negative data derived from, B12(day3, day4, day7, day20) 
B13 (day2, day3), B11(d5) and B22(d6). Gram positive data 
derived From C11(day1), C10( dayl, day2), B20(day1), 
B17(day1, day2), B16(day1,day2) and B15(day2).
Figure 4.14 PBMC obtained from healthy volunteers, Gram negative effluent 
obtained from B13, Gram positive effluent obtained 
from.
Chapter 5
Figure 5.1 (A) Data derived from A1, A3, A4, A5, A6, A7, A8, A9,
A11, B3, B6, B21, B18, B21, C1, C2, C3, C4 and C8.
(B) Data derived from A1, A2, A4, A6, A7, A8, A9, A11, B5, B6, 
B7, B8, B9, C2, C3, C4, C5, C6, C7, C8 and C13.
Figure 5.2 (A) Data derived from A1, A5, C4, C7 
(B) Data derived from A1, A2, C3, C4
Figure 5.3 Data derived from C8, C3, C4, C2
Figure 5.4 Data derived from A1, A2, A4, A11, C2, C3, C4, C8,
Figure 5.5 Data derived from A1, B1, A3, B12, A4, A5, B6, C1, C2, A7, C3,
B8, A8, A10, A11, A6, A7, C3, B21 and C4.
Figure 5.6 Data derived from A1, A2, B4, B5, A5, B6, C1, C2, A6, A6, B7 
and C4.
Figure 5.7 (A) Representative example from A12. Data derived from A12 and 
(B) Data derived from A12 and C5
APPENDIX III: Patient information sheet and consent form
PATIENT INFORMATION SHEET
1. Study title
Inflammation in Peritoneal Dialysis.
Markers of inflammation are the white blood cells that are located in the peritoneal 
cavity of a patient undergoing peritoneal dialysis. The chemicals which are 
responsible for organising these white blood cells can also be measured as markers of 
inflammation.
2. Invitation paragraph
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part.
Thank you for reading this.
3. What is the purpose of the study?
Our immune system fights harmful microbes, such as disease-causing bacteria, 
viruses and tumours by using immune cells which attack these foreign substances. We 
carry numerous immune cells at various locations in our body, including our blood 
and many tissues (including the peritoneal cavity). This study is all about finding out 
more about our peritoneal immune cells. We want to understand how they reach the 
peritoneal cavity, how they recognize microbes and other harmful particles and how 
they protect us during episodes of peritonitis. Answers to these fundamental questions 
are extremely important since recurrent infection (peritonitis) remains the major 
reason for treatment failure in peritoneal dialysis.
4. Why have I been chosen?
You have been invited to take part because you are on peritoneal dialysis and the fluid 
from your exchange would normally be thrown away. We can use this fluid to 
investigate the immune cells in the body.
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5. Do I  have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive.
6. What will happen to me if I take part?
If you agree to take part, we will use some of the fluid that you drain out during your 
PD exchange for research purposes. As you know this fluid would normally be 
thrown away. When the research group get your sample, it will have no details that 
can identify you with it, only a code number. The master copy with your 
identification details will stay with the PD Team and will not be disclosed to the 
researchers
7 What will happen to the sample I give?
The sample you give will be
• processed to isolate immune cells to be used in experiments. The surplus 
of cells (in case not all of the cells have been used) will be stored as 
frozen samples in case the experiment needs to be redone later or you 
agree that we can use the surplus for further research.
• The procedure of cell isolation and tissue culture is not dangerous to you 
(as blood donor) or to the researchers carrying out these experiments.
• Nobody else but the researchers involved in this study have access to your 
donated cells.
• Researchers handling your donated material will not be able to identify 
you, i.e. your material will be labelled with a code whose meaning is only 
known to the clinical personnel collecting your sample.
• If you wish, your sample can be destroyed at anytime (unless it has 
already been used in experiments)
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8. Future research
We would like to store the sample you have given us for use in future research projects. If 
you agree the sample will be stored and may be used in future research into immune cells.
This will be done in accordance with the Human Tissue Act which lays down requirements 
for the storage and use of all samples. No identifiable information will be stored with the 
sample and all research that will be done in the future will have the approval of a Research 
Ethics Committee. If you wish, you can agree for the sample to be used for the current project 
but not for future research. If so, you should only sign Part 1 of the consent form
9. Will any genetic tests be done?
No genetic testing will be done
10. W hat do I have to do?
There are no restrictions on your lifestyle by taking part in this study over and above those 
normally associated with being on peritoneal dialysis.
11. W hat are the possible disadvantages and risks of taking part?
There are no obvious disadvantages to taking part in this study. You should not be 
inconvenienced by taking part as the researcher will come to your house to collect the fluid at 
a time convenient to you. There is a small risk of bruising when having a blood sample taken, 
but as often as possible this will be done as part of your routine care and will not involve you 
in having an extra stab into a vein.
12. W hat are the possible benefits of taking part?
There is no benefit to you from taking part in the trial, however the information we get from 
this study may help us to improve treatment for patients undergoing PD.
13. W hat if something goes wrong?
If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds 
for a legal action but you may have to pay for it. Regardless of this, if you wish to complain, 
or have any concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints mechanisms 
should be available to you. The Complaints Officer can be contacted on 02920.746296
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14. Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be kept 
strictly confidential. No information about you will leave the hospital with your name and 
address on it so you cannot be recognised from it.
15. What will happen if I don’t want to carry on with the study?
You can decide to withdraw from the study at any point. If you want to withdraw you can 
contact the research team and make that request. If the sample has been processed it will not 
be possible to return it to you or destroy it, but the information we have obtained can be 
withdrawn and destroyed. If the sample has not yet been processed it can be destroyed or 
disposed of as you see fit.
16. What will happen to the results of the research study?
The results of this study will be submitted for presentation and publication at PD meetings 
and in medical journals. You will not be identified in any presentation or publication that is 
submitted.
17. Who is organising and funding the research?
This study is being carried out by the Institute of Nephrology using their own research funds. 
No payment is being made to any of the researchers for including you in this study.
18. Who has reviewed the study?
This study has been reviewed by Panel D of the South East Wales Ethics Committee.
20. Contact for Further Information
Professor John Williams: 02920 748432 
Professor Nick Topley: 02920 748432 
Dr G Roberts: 02920 748446
Thank you for taking part in this study
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PATIENT CONSENT FORM
Patient Identification Number for this trial:
Name of Researchers: Prof JD Williams, Prof N Topley, Dr G Roberts
CONSENT FORM 
Title of Project: Inflammation in Peritoneal Dialysis
Please initial box
I confirm that I have read and understand the information------------------------------------- ----------
sheet dated April 2008 (Version 1) for the above study.
I have had the opportunity to consider the information, _______
ask questions and have had these answered satisfactorily.
2 .1 understand that my participation is voluntary and that there 
will be no financial reward for taking part. I am also free to 
withdraw at any time without giving any reason, and without my 
care or legal rights being affected.
3 .1 understand that relevant sections of data collected during the 
study, may be looked at by individuals from regulatory authorities 
or from the NHS Trust, where it is relevant to my taking part in this 
research.I give permission for these individuals to have access to these data.
4 .1 agree to take part in the above study.
Name of Participant Date Signature
Name of Person Date 
taking consent
Signature
